Adeno-associated virus vector delivery of microdystrophin for the treatment of muscular dystrophy

Abstract

To provide adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy.SOLUTION: The invention provides recombinant AAV vectors comprising a miniaturized human micro-dystrophin gene, and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy. The present invention is directed to gene therapy methods that directly reduce the three primary components of connective tissue (collagen 1, collagen 3 and fibronectin) by delivering the microRNA miR29. In this system, the miR29 binds to the 3' UTR of the collagen and fibronectin gene to down-regulate expression. The invention is directed to gene therapy vectors, e.g., AAV, expressing the guide strand of the microRNA miR29, and a method of delivering miR29 to the muscle to reduce and / or prevent fibrosis.SELECTED DRAWING: None

Description

Technical Field

[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 323,163, filed Apr. 15, 2016, and U.S. Provisional Application No. 62 / 473,253, filed Mar. 17, 2017, both of which are incorporated herein by reference in their entirety. Technical Field

[0002] The present invention provides gene therapy vectors, such as adeno-associated virus (AAV) vectors, that express a miniaturized human dystrophin gene, and methods of using these vectors to reduce and prevent fibrosis in subjects suffering from muscular dystrophy. The present invention also provides a combination gene therapy that protects muscle fibers from damage and increases muscle strength.

Background Art

[0003] The importance of muscle mass and strength for daily activities such as movement and breathing, as well as for whole body metabolism, is without question. Impairment of muscle function results in muscle dystrophy (MD), characterized by muscle weakness and wasting, which has a significant impact on quality of life. The most well characterized MDs result from mutations in genes encoding members of the dystrophin-associated protein complex (DAPC). These MDs are due to membrane vulnerability associated with loss of muscle sheath-cytoskeleton tethering by DAPC. Duchenne muscular dystrophy (DMD) is one of the most devastating muscle diseases, affecting 1 in 5000 newborn males.

[0004] This application includes two translational approaches for developing treatments for DMD. Fibrotic infiltration is profound in DMD and is a significant obstacle for any potential therapy. It is also important to consider that gene replacement alone is hampered by the severity of fibrosis already present in very young children with DMD. Indeed, muscle biopsies at the usual age of diagnosis, 4-5 years, show very significant levels of fibrosis.

[0005] DMD is caused by mutations in the DMD gene, resulting in a decrease in mRNA and the absence of dystrophin, a 427kD sarcoplasmic protein associated with the dystrophin-related protein complex (DAPC) (Hoffman et al., Cell 51(6):919-28, 1987). DAPC consists of several proteins in the sarcoplasmic sheath that form structural links between the extracellular matrix (ECM) and the cytoskeleton via dystrophin, an actin-binding protein, and α-dystroglycan, a laminin-binding protein. These structural links act to stabilize the myocyte membrane during contraction and protect against contraction-induced damage. Along with dystrophin loss, membrane fragility leads to sarcoplasmic sheath rupture and calcium influx, inducing calcium-activated protease and segmental fibrillation (Straub et al., Curr Opin. Neurol. 10(2):168-75, 1997). This uncontrolled cycle of muscle degeneration and regeneration eventually depletes the muscle stem cell population (Sacco et al., Cell, 2010.143(7):p.1059-71, Wallace et al., Annu Rev Physiol, 2009.71:p.37-57), leading to progressive muscle weakness, endomysitis, and fibrotic scarring.

[0006] Without membrane stabilization from dystrophin or microdystrophin, DMD exhibits an uncontrolled cycle of tissue damage and repair, ultimately replacing lost muscle fibers with fibrotic scar tissue through connective tissue proliferation. Fibrosis is characterized by excessive deposition of ECM matrix proteins, including collagen and elastin. ECM proteins are primarily produced from cytokines such as TGFβ, released by activated fibroblasts in response to stress and inflammation. While the primary pathological feature of DMD is muscle fiber degeneration and necrosis, fibrosis as a pathological consequence has an equally significant impact. The overproduction of fibrotic tissue limits muscle regeneration and contributes to progressive muscle weakness in DMD patients. In one study, the presence of fibrosis in early DMD muscle biopsies was strongly correlated with poor motor outcomes at 10-year follow-up (Desguerre et al., J Neuropathol Exp Neurol, 2009.68(7):p.762-7). These results point to fibrosis as a major cause of DMD muscle dysfunction and highlight the need to develop therapies to reduce fibrotic tissue. Most anti-fibrotic therapies tested in mdx mice act to block fibrotic cytokine signaling by inhibiting the TGFβ pathway. MicroRNAs (miRNAs) are ~22-nucleotide single-stranded RNAs that mediate gene silencing at the post-transcriptional level by pairing with bases in the 3' UTR of mRNA, inhibiting translation, or promoting mRNA degradation. A 7-bp seed sequence at the 5' end of a miRNA targets the miRNA, and additional recognition is provided by the remainder of the target sequence and its secondary structure. miRNAs play a crucial role in muscle disease pathology and exhibit expression profiles that are uniquely dependent on the type of muscular dystrophy in question (Eisenberg et al. Proc Natl Acad Sci USA, 2007. 104(43):p.17016-21). There is growing evidence suggesting that miRNAs are involved in fibrotic processes in many organs, including the heart, liver, kidneys, and lungs (Jiang et al., Proc Natl). Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17016-21. Recently, downregulation of miR-29 has been shown to contribute to cardiac fibrosis (Cacchiarelli et al., Cell Metab. 2010 Nov;12(4):341-51), and decreased miR-29 expression was genetically associated with muscle in human DMD patients (Eisenberg et al., Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17016-21). The miR-29 family consists of three family members expressed from two bicistronic miRNA clusters. MiR-29a is co-expressed with miR-29b (miR-29b-1), and miR-29c is co-expressed with a second copy of miR-29b (miR-29b-2). The miR-29 family shares a conserved seed sequence, and miR-29a and miR-29b differ from miR-29c by only one nucleotide each. Furthermore, electroporation of miR-29 plasmids (a cluster of miR-29a and miR-29b-1) into mdx mouse muscle decreased the expression levels of ECM components, collagen, and elastin, and significantly reduced collagen deposition in muscle sections within 25 days of treatment (Cacchiarelli et al., Cell Metab. 2010 Nov;12(4):341-51).

[0007] Adeno-associated virus (AAV) is a replication-defective parvovirus, and its single-stranded DNA genome is approximately 4.7 kb in length and contains 145-nucleotide inverted terminal repeats (ITRs). Multiple serotypes of AAV exist. The nucleotide sequences of the genomes of AAV serotypes are known. For example, the nucleotide sequence of the AAV serotype 2 (AAV2) genome is available from Ruffing This is presented in Srivastava et al., J Virol, 45:555-564 (1983), which was modified by et al., J Gen Virol, 75:3385-3392 (1994). Other examples include the complete genome of AAV-1, which is available under GenBank access number NC_002077; the complete genome of AAV-3, which is available under GenBank access number NC_1829; the complete genome of AAV-4, which is available under GenBank access number NC_001829; the genome of AAV-5, which is available under GenBank access number AF085716; the complete genome of AAV-6, which is available under GenBank access number NC_001862; at least portions of the genomes of AAV-7 and AAV-8, which are available under GenBank access numbers AX753246 and AX753249, respectively (see also U.S. Patent Nos. 7,282,199 and 7,790,449 for AAV-8); and the genome of AAV-9, which is available under GenBank access number NC_002077; the complete genome of AAV-3, which is available under GenBank access number NC_1829; the complete genome of AAV-4, which is available under GenBank access number NC_001829; the complete genome of AAV-5, which is available under GenBank access number AF085716; the complete genome of AAV-6, which is available under GenBank access number NC_001862; at least portions of the genomes of AAV-7 and AAV-8, which are available under GenBank access numbers AX753246 and AX753249, respectively (see also U.S. Patent Nos. 7,282,199 and 7,790,449 for AAV-8); and the genome of AAV-9, which is available under GenBank access number NC_002077; the complete genome of AAV-3, which is available under GenBank access number NC_1829; the complete genome of AAV-4, which is available under GenBank access number NC_001829; The AAV-10 genome is available in al., J. Virol., 78:6381-6388 (2004), the AAV-11 genome is available in Mol. Ther., 13(1):67-76 (2006), and the AAV-11 genome is available in Virology, 330(2):375-383 (2004). The AAVrh74 serotype is described in Rodino-Klapac et al. J. Trans. Med. 5:45 (2007). The Cis action sequence, which directs viral DNA replication (rep), capsid formation / packaging, and integration into host cell chromosomes, is contained within the ITR. Three AAV promoters (named p5, p19, and p40 relative to their relative map locations) drive the expression of two AAV internal open reading frames encoding the rep and cap genes. Differential splicing of a single AAV intron (e.g., at AAV2 nucleotides 2107 and 2227) ligates two rep promoters (p5 and p19), resulting in the generation of four rep proteins (rep78, rep68, rep52, and rep40) from the rep gene. These rep proteins possess multiple enzymatic properties that ultimately contribute to the replication of the viral genome.The cap gene is expressed from the p40 promoter and encodes three capsid proteins: VP1, VP2, and VP3. Alternative splicing and non-consensus translation initiation sites are involved in the production of the three related capsid proteins. A single-consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, Current Topics in Microbiology and Immunology, 158:97-129 (1992).

[0008] AAV possesses unique characteristics that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is non-cellular, and natural infection in humans and other animals is silent and asymptomatic. Furthermore, AAV can infect many mammalian cells, enabling the potential to target many different tissues in vivo. Additionally, AAV can transduce slow-dividing and non-dividing cells and persist essentially for the lifetime of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV proviral genome is infectious as cloned DNA within a plasmid, enabling the construction of recombinant genomes. Furthermore, since the signals directing AAV replication, genomic capsid formation, and integration are contained within the ITR of the AAV genome, part or all of the internal approximately 4.3 kb of genome (rep-cap encoding replication and structural capsid proteins) may be replaced with foreign DNA, such as a gene cassette containing the promoter, the DNA of interest, and polyadenylation signals. The rep and cap proteins may be supplied trans. Another important characteristic of AAV is that it is an extremely stable and robust virus. This means it readily withstands the conditions used to inactivate adenoviruses (56°C–65°C for several hours), reducing the importance of chilling AAV. AAV can be freeze-dried. Finally, AAV-infected cells do not show resistance to co-infection.

[0009] Multiple studies have demonstrated long-term (over 1.5 years) recombinant AAV-mediated protein expression in muscle. See Clark et al., Hum Gene Ther, 8:659-669 (1997), Kessler et al., Proc Nat. Acad Sc. USA, 93:14082-14087 (1996), and Xiao et al., J Virol, 70:8098-8108 (1996). See also Chao et al., Mol Ther, 2:619-623 (2000) and Chao et al., Mol Ther, 4:217-222 (2001). Furthermore, because muscles undergo high levels of angiogenesis, recombinant AAV transduction resulted in the appearance of the transgene product in the systemic circulation after intramuscular injection, as described by Herzog et al., Proc Natl Acad Sci USA, 94:5804-5809 (1997) and Murphy et al., Proc Natl Acad Sci USA, 94:13921-13926 (1997). In addition, Lewis et al., J Virol, 76:8769-8775 (2002) demonstrated that skeletal muscle fibers possess the cellular factors necessary for correct antibody glycosylation, folding, and secretion, showing that muscles can stably express secreted protein therapeutics. Improving function in patients with DMD and other muscular dystrophy requires both gene restoration and fibrosis reduction. There is a need for gene restoration methods to reduce fibrosis that can be repaired, leading to more effective treatments for DMD and other muscular dystrophy. miR29 is a potential gene regulator for reducing muscular fibrosis and is an ideal candidate. [Prior art documents] [Non-patent literature]

[0010] [Non-Patent Document 1] Hoffman et al., Cell 51(6):919-28,1987 [Overview of the project] [Means for solving the problem]

[0011] This invention relates to gene therapy that directly reduces three major components of connective tissue (collagen 1, collagen 3, and fibronectin) by delivering the microRNA miR29. In this system, miR29 binds to the 3'UTR of collagen and fibronectin genes and downregulates their expression. This invention relates to gene therapy vectors expressing the microRNA guide strand miR29, such as AAV, and methods for delivering miR29 to muscle to alleviate and / or prevent fibrosis.

[0012] Furthermore, the present invention provides combination therapies and approaches for reducing and preventing fibrosis using a gene therapy vector that delivers miR-29, which suppresses fibrosis, together with microdystrophin, which addresses the gene deficiency observed in DMD. As shown in Examples 5-7, the combination therapy resulted in greater reduction of fibrosis, increased muscle size, and increased muscle strength.

[0013] In one embodiment, the present invention provides an rAAV vector expressing miR-29. For example, the rAAV vector includes a polynucleotide sequence expressing miR29c, such as a miR-29c target guide strand of SEQ ID NO: 3, a miR-29c guide strand of SEQ ID NO: 4, and a nucleotide sequence containing the native miR-30 and stem-loop (SEQ ID NO: 5). An exemplary polynucleotide sequence containing miR-29c cDNA in the miR-30 backbone is shown as SEQ ID NO: 2 (Figure 1).

[0014] An exemplary rAAV of the present invention is pAAV.CMV.Mir29C containing the nucleotide sequence of SEQ ID NO: 1, where the CMV promoter extends from nucleotides 120 to 526, the EF1a intron extends from nucleotides 927 to 1087 and 1380 to 1854, the miR-29c guide stand extends from nucleotides 1257 to 1284, the shRNA-miR29-c having a primary seed sequence extends from nucleotides 1088 to 1375, and the polyA sequence extends from nucleotides 1896 to 2091. In one embodiment, the rAAV vector of the present invention is AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV12, or AAV13.

[0015] Another exemplary rAAV of the present invention is pAAV.MHC.Mir29C containing the nucleotide sequence of SEQ ID NO: 12, where the MCK enhancer extends from nucleotides 190 to 395, the MHC promoter extends from nucleotides 396 to 753, the EF1a introns extend from nucleotides 1155 to 1315 and 1609 to 2083, the guide strand of miR-29c extends from nucleotides 1487 to 1512, the shRNA-miR29-c having a primary seed sequence extends from nucleotides 1316 to 1608, and the polyA sequence extends from nucleotides 2094 to 2146. In one embodiment, the rAAV vector of the present invention is AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV12, or AAV13.

[0016] In another embodiment, the rAAV vector of the present invention can be operably linked to muscle-specific regulatory elements. For example, muscle-specific regulatory elements include human skeletal actin gene elements, cardiac actin gene elements, muscle cell-specific enhancer-binding factors (MEFs), muscle creatine kinase (MCK), tMCK (shortened MCK), myosin heavy chain (MHC), C5-12 (synthetic promoter), mouse creatine kinase enhancer elements, skeletal fast-twitch muscle troponin C gene elements, slow-twitch muscle cardiac troponin C gene elements, slow-twitch muscle troponin I gene elements, hypoxia-induced nuclear factor, steroid-induced elements, or glucocorticoid response elements (GREs).

[0017] For example, any of the rAAV vectors of the present invention can be operably linked to a muscle-specific control element comprising the MCK enhancer nucleotide sequence of SEQ ID NO: 10 and / or the MCK promoter sequence of SEQ ID NO: 11.

[0018] The present invention also provides a pharmaceutical composition (or, as may be referred to herein simply as "composition") comprising any of the rAAV vectors of the present invention.

[0019] In another embodiment, the present invention provides a method for producing rAAV vector particles, comprising culturing cells transfected with any of the rAAV vectors of the present invention and recovering rAAV particles from the supernatant of the transfected cells. The present invention also provides viral particles comprising any of the recombinant AAV vectors of the present invention.

[0020] In another embodiment, the present invention provides a method for alleviating fibrosis in a subject in need, comprising administering any rAAV vector of the present invention expressing a therapeutically effective amount of miR-29. For example, any of the rAAVs of the present invention is administered to a subject suffering from muscular dystrophy to alleviate fibrosis, particularly fibrosis in the subject's skeletal or cardiac muscle. These methods may further include the step of administering an rAAV vector expressing microdystrophin.

[0021] "Fibrosis" refers to the excessive or uncontrolled deposition of extracellular matrix (ECM) components and the abnormal repair process in post-injury tissues, including skeletal muscle, cardiac muscle, liver, lungs, kidneys, and pancreas. The deposited ECM components include fibronectin and collagen, such as collagen 1, collagen 2, or collagen 3.

[0022] In another embodiment, the present invention provides a method for preventing fibrosis in a subject of need, comprising administering any recombinant AAV vector of the present invention expressing a therapeutically effective amount of miR-29. For example, any of the rAAVs of the present invention may be administered to a subject with muscular dystrophy to prevent fibrosis, for example, the rAAV of the present invention expressing miR-29 may be administered before fibrosis is observed in the subject. Furthermore, the rAAV of the present invention expressing miR-29 may be administered to subjects at risk of developing fibrosis, such as those with or diagnosed with muscular dystrophy, for example, DMD. The rAAVs of the present invention may be administered to subjects with muscular dystrophy to prevent new fibrosis in these subjects. These methods may further include the step of administering an rAAV vector expressing microdystrophin.

[0023] The present invention also provides a method for increasing muscle strength and / or muscle mass in subjects suffering from muscular dystrophy, comprising administering one of the present invention's rAAV vectors expressing a therapeutically effective amount of miR-29. These methods may further include the step of administering an rAAV vector expressing microdystrophin. The terms "combination therapy" and "combination treatment" refer to the administration of the rAAV vector expressing miR-29 and the rAAV vector expressing microdystrophin according to the present invention.

[0024] In any of the methods of the present invention, the subject may have a muscular dystrophy such as DMD, Becker muscular dystrophy, or any other dystrophin-related muscular dystrophy. In addition, in any of the methods of the present invention, the subject may have a dystrophin disorder.

[0025] In another embodiment, the present invention provides a recombinant AAV vector comprising a nucleotide sequence encoding a microdystrophin protein. The present invention provides an rAAV comprising a) a nucleotide sequence having at least 85% identity with the nucleotide sequence of SEQ ID NO: 7 and encoding a functional microdystrophin protein, b) the nucleotide sequence of SEQ ID NO: 7, or c) the nucleotide sequence of SEQ ID NO: 9.

[0026] An exemplary rAAV expressing the microdystrophin of the present invention comprises the nucleotide sequence of SEQ ID NO: 9 and is pAAV.mck.microdystrophin as shown in Figures 10 and 11. This rAAV vector comprises an MCK promoter, a chimeric intron sequence, the coding sequence of the microdystrophin gene, poly(A), ampicillin resistance, and a pGEX plasmid backbone having a pBR322 origin or replication. In one embodiment, the recombinant AAV vector of the present invention is AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh.74, AAV8, AAV9, AAV10, AAV11, AAV12, or AAV13.

[0027] The present invention provides an rAAV vector encoding a microdystrophin protein having sequence identity of, for example, SEQ ID NO: 8 with at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94%, and even more typically at least 95%, 96%, 97%, 98%, or 99%, the protein retaining microdystrophin activity. Microdystrophin proteins provide stability to the fascia during muscle contraction, for example, microdystrophin acts as a shock absorber during muscle contraction.

[0028] The present invention provides an rAAV vector for expressing a microdystrophin that has sequence identity with, for example, SEQ ID NO: 7 of at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94%, and even more typically at least 95%, 96%, 97%, 98%, or 99%, and contains a nucleotide sequence encoding a functional microdystrophin protein.

[0029] The present invention provides an rAAV vector that expresses a microdystrophin containing a nucleotide sequence encoding a functional microdystrophin protein, which hybridizes to the nucleic acid sequence of SEQ ID NO: 7 or its complement under stringent conditions.

[0030] The term "stringent" is used to refer to conditions that are generally understood as stringent in the art. Hybridization stringency is primarily determined by temperature, ionic strength, and the concentration of denaturing agents such as formamide. Examples of stringent conditions for hybridization and washing are 0.015 M sodium chloride, 0.0015 M sodium citrate at 65–68°C or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at 42°C. See Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, NY 1989). More stringent conditions (higher temperature, lower ionic strength, higher formamide, or other denaturing agents, etc.) may also be used, but these will affect the rate of hybridization. In cases where deoxyoligonucleotide hybridization is a concern, additional exemplary stringent hybridization conditions include washing in 0.05% sodium pyrophosphate of 6×SSC at 37°C (14-base oligo), 48°C (17-base oligo), 55°C (20-base oligo), and 60°C (23-base oligo).

[0031] Other agents may be included in the hybridization and washing buffers to reduce nonspecific and / or background hybridization. Examples include 0.1% bovine serum albumin, 0.1% polyvinylpyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecyl sulfate, NaDodSO4, (SDS), Ficol, Denhardt's solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, but other suitable agents may also be used. The concentrations and types of these additives can be varied without substantially affecting the stringency of the hybridization conditions. Hybridization experiments are typically performed in sections 6.8–7.4, but under typical ionic strength conditions, the rate of hybridization is almost independent of pH. See Anderson et al., Nucleic Acid Hybridization: A Practical Approach, Ch.4, IRL Press Limited (Oxford, England). Hybridization conditions can be adjusted by those skilled in the art to adapt these variables and allow DNAs with different sequence relationships to form hybrids.

[0032] In another embodiment, an rAAV vector expressing microdystrophin contains a coding sequence for the microdystrophin gene operably linked to a muscle-specific regulatory element. For example, the muscle-specific regulatory element may be a human skeletal actin gene element, a cardiac actin gene element, a muscle cell-specific enhancer binding factor (MEF), muscle creatine kinase (MCK), tMCK (truncate MCK), myosin heavy chain (MHC), C5-12 (synthetic promoter), a mouse creatine kinase enhancer element, a skeletal fast-twitch muscle troponin C gene element, a slow-twitch muscle cardiac troponin C gene element, a slow-twitch muscle troponin I gene element, a hypoxia-induced nuclear factor, a steroid-induced element, or a glucocorticoid response element (GRE).

[0033] Furthermore, the present invention provides an rAAV vector that expresses a microdystrophin containing a muscle-specific regulatory element comprising the nucleotide sequence of SEQ ID NO: 10 or SEQ ID NO: 11.

[0034] The present invention also provides a pharmaceutical composition (or, as may be referred to herein simply as "composition") comprising any of the rAAV vectors of the present invention.

[0035] In another embodiment, the present invention provides a method for producing rAAV vector particles, comprising culturing cells transfected with any of the rAAV vectors of the present invention and recovering rAAV particles from the supernatant of the transfected cells. The present invention also provides viral particles comprising any of the recombinant AAV vectors of the present invention.

[0036] The present invention also provides a method for producing a functional microdystrophin protein, comprising infecting host cells with a recombinant AAV vector expressing the microdystrophin of the present invention and expressing a functional microdystrophin protein in the host cells.

[0037] In another embodiment, the present invention provides a method for alleviating fibrosis in a subject requiring attention, comprising administering any rAAV vector of the present invention expressing a therapeutically effective amount of microdystrophin. For example, any of the rAAVs of the present invention may be administered to a subject suffering from muscular dystrophy or dystrophin disorder to alleviate fibrosis, particularly in the skeletal or cardiac muscle of the subject.

[0038] In another embodiment, the present invention provides a method for preventing fibrosis in a subject of need, comprising administering any recombinant AAV vector of the present invention expressing a therapeutically effective amount of microdystrophin. For example, any of the rAAVs of the present invention may be administered to a subject suffering from muscular dystrophy or dystrophinic disorder to prevent fibrosis, for example, an rAAV of the present invention expressing microdystrophin may be administered before fibrosis is observed in the subject. Furthermore, an rAAV of the present invention expressing microdystrophin may be administered to a subject at risk of developing fibrosis, such as a subject suffering from or diagnosed with dystrophinic disorder or muscular dystrophy, for example, DMD or Becker muscular dystrophy. An rAAV of the present invention may be administered to a subject suffering from dystrophinic disorder or dystrophinic muscular dystrophy to prevent new fibrosis in these subjects.

[0039] The present invention also provides a method for increasing muscle strength and / or muscle mass in subjects suffering from muscular dystrophy or dystrophinic disorder, comprising administering one of the present invention's rAAV vectors expressing a therapeutically effective amount of miR-29.

[0040] Any of the methods described above, comprising the step of administering an rAAV expressing miR-29c of the present invention, may further comprise the step of administering any of the rAAVs expressing microdystrophin described herein. The terms “combination therapy” and “combination treatment” refer to the administration of the rAAV vector expressing miR-29 and the rAAV vector expressing microdystrophin of the present invention.

[0041] In a method for administering an rAAV vector expressing miR-29 and an rAAV vector expressing microdystrophin protein, these rAAV vectors may be administered simultaneously, or the rAAV vector expressing miR29 may be administered immediately before the rAAV expressing microdystrophin protein and administered consecutively, or the rAAV vector expressing miR29 may be administered immediately after the rAAV expressing microdystrophin protein and administered consecutively. Alternatively, the method of the present invention may be carried out in which the AAV vector expressing microdystrophin protein is administered approximately 1 to 5 hours, 5 to 12 hours, 12 to 15 hours, or 15 to 24 hours after the administration of the rAAV expressing miR-29, or the method of the present invention may be carried out in which the AAV vector expressing microdystrophin protein is administered approximately 1 to 5 hours, 5 to 12 hours, 12 to 15 hours, or 15 to 24 hours before the administration of the rAAV expressing miR-29c. Alternatively, the present invention may be carried out in which an AAV vector expressing microdystrophin protein is administered within approximately 1, 6, 12, or 24 hours after administration of an rAAV expressing miR-29, or in which the present invention may be carried out in which an AAV vector expressing microdystrophin protein is administered within approximately 1, 6, 12, or 24 hours before administration of an rAAV expressing miR-29c.

[0042] The present invention aims to administer one of the AAV vectors of the present invention to patients diagnosed with dystrophin disorders or muscular dystrophy, such as DMD or Becker muscular dystrophy, before fibrosis is observed in the subject, before muscle strength declines, or before muscle mass decreases in the subject.

[0043] The present invention also intends to administer any of the rAAVs of the present invention to subjects suffering from dystrophin disorders or muscular dystrophy, such as DMD or Becker muscular dystrophy, who have already developed fibrosis, in order to prevent further fibrosis in these subjects. The present invention also provides to administer any of the rAAVs of the present invention to patients suffering from muscular dystrophy who already have reduced muscle strength or muscle mass, in order to protect the muscles from further damage.

[0044] In any of the methods of the present invention, the rAAV vector is administered by intramuscular or intravenous injection.

[0045] In addition, in any of the methods of the present invention, the rAAV vector is administered systemically. For example, the rAAV vector or composition is administered parenterally by injection, infusion, or implantation.

[0046] In another embodiment, the present invention provides compositions for alleviating fibrosis in subjects requiring it, comprising either a miR29-expressing rAAV vector or a microdystrophin-expressing rAAV vector, or both a miR-29-expressing rAAV vector and a microdystrophin-expressing rAAV vector. Furthermore, the present invention provides compositions for preventing fibrosis in patients suffering from dystrophin disorders or muscular dystrophy, such as DMD or Becker muscular dystrophy, comprising either a miR29-expressing recombinant AAV vector or a microdystrophin-expressing rAAV vector, or both a miR-29-expressing rAAV vector and a microdystrophin-expressing rAAV vector.

[0047] The present invention also provides compositions for increasing muscle strength and / or muscle mass in subjects suffering from dystrophin disorders or muscular dystrophy, such as DMD or Becker muscular dystrophy, comprising either any of the rAAV vectors of the present invention expressing miR29 or any of the rAAV vectors expressing microdystrophin protein, or both of the rAAV vectors expressing miR-29 and the rAAV vectors expressing microdystrophin protein.

[0048] In further embodiments, the present invention provides compositions for the treatment of dystrophin disorders or muscular dystrophy, such as DMD or Becker muscular dystrophy, comprising either any of the rAAV vectors of the present invention expressing miR29 or any of the rAAV vectors expressing microdystrophin protein, or both of the rAAV vectors expressing miR-29 and the rAAV vectors expressing microdystrophin protein.

[0049] The compositions of the present invention are formulated for intramuscular or intravenous injection. The compositions of the present invention are also formulated for systemic administration, such as parenteral administration by injection, infusion, or implantation. Furthermore, any of the compositions are formulated for administration to subjects suffering from dystrophin disorders or muscular dystrophy, such as DMD, Becker dystrophy, or any other dystrophin-related muscular dystrophy.

[0050] In further embodiments, the present invention provides for the preparation of agents for alleviating fibrosis in subjects requiring treatment, comprising either the rAAV vector expressing miR29 or the rAAV vector expressing microdystrophin, or both the rAAV vector expressing miR-29 and the rAAV vector expressing microdystrophin. For example, a subject suffers from a dystrophin disorder or muscular dystrophy, such as DMD, Becker muscular dystrophy, or any other dystrophin-related muscular dystrophy, and requires treatment.

[0051] In another embodiment, the present invention provides a use for the preparation of agents for preventing fibrosis in subjects suffering from muscular dystrophy, comprising either any of the rAAV vectors of the present invention expressing miR29 or any of the rAAV vectors expressing microdystrophin, or both of the rAAV vectors expressing miR-29 and the rAAV vectors expressing microdystrophin. In addition, the present invention provides a use for the preparation of agents for increasing muscle strength and / or muscle mass in subjects suffering from dystrophin disorders or muscular dystrophy, such as DMD or Becker muscular dystrophy, comprising either any of the recombinant AAV vectors of the present invention expressing miR29 or any of the rAAV vectors expressing microdystrophin, or both of the rAAV vectors expressing miR-29 and the rAAV vectors expressing microdystrophin.

[0052] The present invention intends to use any of the AAV vectors of the present invention for the preparation of drugs to be administered to patients diagnosed with DMD before fibrosis is observed in the subject, or before muscle weakness or muscle mass decreases in the subject.

[0053] The present invention also intends to use any of the AAV vectors of the present invention for the preparation of a drug for administration to subjects with muscular dystrophy who have already developed fibrosis, in order to prevent further fibrosis in these subjects. The present invention also provides for administering any of the rAAVs of the present invention to patients with muscular dystrophy who have already experienced muscle weakness or decreased muscle mass, in order to protect the muscles from further damage.

[0054] The present invention also provides for the preparation of agents for the treatment of muscular dystrophy, comprising either the rAAV vector expressing miR296 or the rAAV vector expressing microdystrophin, or both the rAAV vector expressing miR-29 and the rAAV vector expressing microdystrophin.

[0055] In any of the uses of the present invention, the drug is formulated for intramuscular injection. Furthermore, any of the drugs may be prepared for administration to subjects suffering from muscular dystrophy, such as DMD or any other dystrophin-related muscular dystrophy.

[0056] Furthermore, any of the agents of the present invention may be a combination therapy in which a miR-29 expressing rAAV vector and a microdystrophin expressing rAAV vector are administered simultaneously, or a miR29 expressing rAAV vector is administered immediately before the microdystrophin expressing rAAV and then administered consecutively, or a miR29 expressing rAAV vector is administered immediately after the microdystrophin expressing rAAV and then administered consecutively. Alternatively, the agent may include the administration of a microdystrophin expressing AAV vector administered approximately 1 to 5 hours after the administration of a miR-29 expressing rAAV, or the agent may include a microdystrophin expressing AAV vector administered approximately 1 to 5 hours before the administration of a miR-29c expressing rAAV. The present invention provides, for example, the following items: (Item 1) a) A nucleotide sequence having at least 85% identity with the nucleotide sequence of Sequence ID No. 7, which encodes a functional microdystrophin protein, b) The nucleotide sequence of Sequence ID No. 7, or c) A recombinant AAV vector containing the nucleotide sequence of SEQ ID NO: 9. (Item 2) The recombinant AAV vector described in item 1, wherein the vector is serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAVrh74, AAV8, AAV9, AAV10, AAV11, AAV12, or AAV13. (Item 3) The recombinant AAV vector according to item 1 or 2, wherein the polynucleotide sequence is operably linked to a muscle-specific regulatory element. (Item 4) The recombinant AAV vector described in item 3, wherein the muscle-specific regulatory element is a human skeletal actin gene element, a cardiac actin gene element, a muscle cell-specific enhancer binding factor mef, muscle creatine kinase (MCK), truncated MCK (tMCK), myosin heavy chain (MHC), C5-12, a mouse creatine kinase enhancer element, a skeletal fast-twitch muscle troponin C gene element, a slow-twitch muscle cardiac troponin C gene element, a slow-twitch muscle troponin I gene element, a hypoxia-induced nuclear factor, a steroid-induced element, or a glucocorticoid response element (gre). (Item 5) The recombinant AAV vector according to item 3 or 4, wherein the muscle-specific regulatory element comprises the nucleotide sequence of SEQ ID NO: 10 or SEQ ID NO: 11. (Item 6) A composition comprising a recombinant AAV vector as described in any one of items 1 to 5. (Item 7) A method for treating muscular dystrophy or dystrophin disorders, comprising administering a therapeutically effective dose of a recombinant AAV vector described in any one of items 1 to 5 or a composition described in item 6. (Item 8) A method for reducing or preventing fibrosis in a subject suffering from muscular dystrophy or dystrophinic disorder, comprising administering a therapeutically effective dose of a recombinant AAV vector described in any one of items 1 to 5 or a composition described in item 6. (Item 9) A method for increasing muscle strength or muscle mass in a subject suffering from muscular dystrophy or dystrophinic disorder, comprising administering a therapeutically effective dose of a recombinant AAV vector described in any one of items 1 to 5 or a composition described in item 6. (Item 10) The method according to any one of items 7 to 9, wherein the recombinant AAV vector or the composition is administered by intramuscular injection, intravenous injection, parenteral administration, or systemic administration. (Item 11) The method according to any one of items 7 to 10, wherein the recombinant AAV is administered before fibrosis is observed in the subject, or before muscle strength decreases in the subject, or before muscle mass decreases in the subject. (Item 12) The method according to any one of items 7 to 11, wherein the muscular dystrophy is Duchenne muscular dystrophy or Becker muscular dystrophy. (Item 13) A composition comprising a recombinant AAV vector as described in any one of items 1 to 5, for the treatment of muscular dystrophy. (Item 14) A composition comprising a recombinant AAV vector as described in any one of items 1 to 5, for the purpose of reducing or preventing fibrosis in subjects suffering from muscular dystrophy. (Item 15) A composition comprising a recombinant AAV vector according to any one of items 1 to 5 for increasing muscle strength in subjects suffering from muscular dystrophy. (Item 16) The composition according to any one of items 13 to 15, wherein the composition is administered before fibrosis is observed in the subject, or before muscle strength decreases in the subject, or before muscle mass decreases in the subject. (Item 17) The composition according to any one of items 13 to 16, wherein the subject is suffering from Duchenne muscular dystrophy or Becker muscular dystrophy. (Item 18) Use of recombinant AAV vectors described in any one of items 1 to 5 or compositions described in item 6 for the preparation of drugs for the treatment of muscular dystrophy. (Item 19) Use of a recombinant AAV vector described in any one of items 1 to 5 or a composition described in item 6 for the preparation of a drug for the alleviation or prevention of fibrosis in subjects suffering from muscular dystrophy. (Item 20) Use of a recombinant AAV vector described in any one of items 1 to 5 or a composition described in item 6 for the preparation of drugs for increasing muscle strength or muscle mass in subjects suffering from muscular dystrophy. (Item 21) The use of the drug as described in any one of items 16 to 18, wherein the drug is administered before fibrosis is observed in the subject, or before muscle strength decreases in the subject, or before muscle mass decreases in the subject. (Item 22) Use as described in any one of items 18-21, provided that the subject is suffering from Duchenne muscular dystrophy or Becker muscular dystrophy. (Item 23) The composition or use described in any one of items 13 to 22, wherein the composition or drug is formulated for intramuscular administration, intravenous injection, parenteral administration, or systemic administration. (Item 21) A method for producing a functional microdystrophin protein, comprising infecting host cells with a recombinant AAV vector described in any one of items 1 to 5, and expressing a functional microdystrophin protein in the host cells. [Brief explanation of the drawing]

[0057] [Figure 1] This provides the nucleotide sequence of miR-29c in the rAAV vector scAAVCrh.74.CMV.miR29c and in the natural miR-30 skeleton, as well as a schematic diagram of the nucleotide sequence of the predicted hairpin structure. [Figure 2A]This study demonstrates that injection of miR-29c into muscle reduces overall muscle collagen and restores miR-29c expression. [Figure 2B] Same as above. [Figure 2C] Same as above. [Figure 3A] This study shows that injection of miR-29c improves absolute muscle strength (Panel A) and specific muscle strength (Panel B), but does not protect against contraction-induced injury (Panel C). [Figure 3B] Same as above. [Figure 3C] Same as above. [Figure 4A] This shows the number of microdystrophins expressed in muscle fibers, which measures the effectiveness of transgene delivery. [Figure 4B] Same as above. [Figure 4C] Same as above. [Figure 5A] Co-delivery of miR-29c with microdystrophin reduces collagen expression (Panel A) and fibrosis-induced dystrophin expression. [Figure 5B] Same as above. [Figure 5C] Same as above. [Figure 6A] Intramuscular injection of miR-29c / microdystrophin inhibits the extracellular matrix in mdx / utrn+ / - mice, as measured by collagen-1-alpha (Panel A), collagen-3-alpha (Panel B), fibronectin (Panel C), and TGF-β (Panel D). [Figure 6B] Same as above. [Figure 6C] Same as above. [Figure 6D] Same as above. [Figure 7A] This study demonstrates that intramuscular injection of miR-29c increased absolute force in muscles (Panel A), normalized specific force (Panel B), and added protection from contraction-induced injury (Panel C). [Figure 7B] Same as above. [Figure 7C] Same as above. [Figure 8]This study demonstrates that the combination therapy of miR-29c / μ-dys increases muscle size in mice treated at 3 months of age. Sections of treated and untreated mdx / utrn+ / - gastrocnemius muscle stained with picrosilius red, which stains collagen, are shown. Fibrotic areas are pink, while intact muscle is green. At a macroscopic level, the combination therapy of miR-29c / μ-dys reduces fibrosis and increases total cross-sectional area. [Figure 9A] Treatment with miR-29c delivered co-delivered with microdystrophin increased muscle hypertrophy and hyperplasia compared to either injection alone, as indicated by increased total weight of injected gastrocnemius muscle (Panel A), increased mean fiber size (Panel B), increased muscle cross-sectional area (Panel D, uninjected: 24.6 vs. miR-29c: 26.3 vs. microdys: 26.6 vs. microdys / miR-29c: 33.1), and increased muscle fiber number (Panel E), but the number of muscle fibers per unit area was unaffected (Panel F). Panel C compares mdx / utrn+ / - controls with miR-29c / μ-dys-treated mdx / utrn+ / -, showing an increase in mean diameter from 25.96 to 30.97 μm. [Figure 9B] Same as above. [Figure 9C] Same as above. [Figure 9D] Same as above. [Figure 9E] Same as above. [Figure 9F] Same as above. [Figure 10A]This study demonstrates that early treatment with AAV.miR-29c / microdystrophin combination therapy is more effective in reducing fibrosis and ECM development. Panel A shows picrosilius red staining of mice that were injected with AAV.miR-29c, AAV.microdystrophin, and AAV.miR-29c / AAV.microdystrophin at 4-5 weeks of age, and then removed 12 weeks after injection. Panel B provides quantification of picrosilius red staining, showing that combination-treated muscle had a 51.1% reduction in collagen compared to uninjected GAS muscle. Panel C demonstrates that qRT-PCR confirms increased miR-29c transcript levels in the treated cohort. Semi-quantitative qRT-PCR shows significant reductions in collagen I and III (panels d, e), fbn (panel f), and TGF-β1 (panel g) levels in AAV.miR-29c / AAV.microdystrophin-treated muscle compared to the contralateral limb and monotherapy, respectively. Error bars, SEM of n=5 (scAAVrh.74.CMV.miR-29c), n=5 (scAAVrh.74.CMV.miR-29c / ssAAVrh.74.MCK.microdystrophin), n=6 (ssAAVrh.74.MCK.microdystrophin), n=9 (mdx / utrn+ / - mice). One-way ANOVA (*p<0.05, **p<0.01, ***p<0.001) [Figure 10B] Same as above. [Figure 10C] Same as above. [Figure 10D] Same as above. [Figure 10E] Same as above. [Figure 10F] Same as above. [Figure 10G] Same as above. [Figure 11]This study demonstrates that early combination therapy restores strength and protects against contraction-induced injury. Absolute (Panel A) and normalized specific force (Panel B) measurements after tetanic contraction were significantly increased in GAS muscle injected with all three treatments compared to untreated mdx / utrn+ / - muscle (Panel C). Muscles were then evaluated for force loss after repetitive eccentric contractions. Only mice treated with combination therapy with miR-29c / microdystrophin and those treated with microdystrophin monotherapy showed protection from force loss compared to untreated mdx / utrn+ / - muscle (blue). Two-way ANOVA demonstrates significance in the decay curves. Error bars, SEM of n=5 (rAAVrh.74.CMV.miR-29c), n=6 (rAAVrh.74.CMV.miR-29c / rAAVrh.74.MCK.microdystrophin), n=5 (rAAVrh.74.MCK.microdystrophin), n=15 (mdx / utrn+ / -mouse). One-way ANOVA (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). [Figure 12] This study demonstrates that miR-29c / microdystrophin combination therapy increases muscle size in mice treated at 1 month of age. Treated and untreated mdx / utrn+ / -GAS muscle tissue was sectioned and stained with picrosilius red, which stains collagen. Fibrotic areas are pink, while intact muscle is green. At a macroscopic level, the miR-29c / microdystrophin combination reduces fibrosis and increases total cross-sectional area. [Figure 13A]This study demonstrates that early treatment (4-5 weeks) with AAV.MCK.miR-29c / microdystrophin combination therapy is more effective in reducing fibrosis and ECM development. Panel A provides picrosilius red staining of mice that were uninjected and those injected with AAV.MCK.miR-29c / AAV.MCK.microdystrophin at 4-5 weeks of age and removed 12 weeks after injection. At original magnification, Panel B provides quantification of picrosilius red staining showing that the combination-treated muscle had a 50.9% reduction in collagen compared to untreated GAS muscle. Panel C provides qRT-PCR confirming increased miR-29c transcript levels in the treated cohort. Semi-quantitative qRT-PCR showed significant reductions in collagen 1A (Col1A, panel D) and collagen 3A (Col3A, panel E), fibronectin (Fbn, panel F), and Tgfβ1 (panel G) levels in AAV.MCK.miR-29c / AAV.microdystrophin-treated muscle compared to the contralateral limb. (*p<0.05, ****p<0.0001). [Figure 13B] Same as above. [Figure 13C] Same as above. [Figure 13D] Same as above. [Figure 13E] Same as above. [Figure 13F] Same as above. [Figure 13G] Same as above. [Figure 14A]This study demonstrates that late-stage treatment (treatment at 12 weeks) with AAV.MCK.miR-29c / microdystrophin combination therapy is effective in reducing fibrosis and ECM development. Panel A provides picrosilius red staining of untreated, AAV.MCK.miR-29c, and AAV.MCK.miR-29c / AAV.microdystrophin 12 weeks after injection. Original magnification, 20x. Panel B provides quantification of picrosilius red staining showing that combination-treated muscle had a 30.3% decrease in collagen compared to untreated GAS muscle. Panel C provides qRT-PCR confirming increased miR-29c transcript levels in the treated cohort. Semi-quantitative qRT-PCR demonstrated significant reductions in collagen 1A (Col1A, panel D), collagen 3A (Col3A, panel E), fibronectin (Fbn, panel F), and Tgfβ1 (panel G) levels in AAV.miR-29c / AAV.microdystrophin-treated muscle compared to the contralateral limb. One-way ANOVA. All data represent mean ± SEM. (**p<0.01, ****p<0.0001). [Figure 14B] Same as above. [Figure 14C] Same as above. [Figure 14D] Same as above. [Figure 14E] Same as above. [Figure 14F] Same as above. [Figure 14G] Same as above. [Figure 15A] This study demonstrates that early combination therapy (treatment at 4-5 weeks) restored strength and protected against contraction-induced injury. Absolute (Panel A) and normalized specific force (Panel B) after tetanic contraction were significantly increased in GAS muscle injected with MCK.miR-29c and microdystrophin compared to untreated mdx / utrn+ / - muscle. (C) Muscle was then evaluated for force loss after repetitive eccentric contraction. Mice treated with combination therapy with miR-29c / microdystrophin and those treated with microdystrophin monotherapy showed protection from force loss compared to untreated mdx / utrn+ / - muscle (red). Two-way ANOVA. All data represent mean ± SEM (****P<0.0001). [Figure 15B] Same as above. [Figure 15C] Same as above. [Figure 16A] This study demonstrates that late-stage combination therapy restored strength and protected against contraction-induced injury. Absolute (Panel A) and normalized specific force (Panel B) after tetanic contraction were significantly increased in GAS muscle injected with rAAV expressing rAAV.MCK.miR-29c and microdystrophin, compared to untreated mdx / utrn+ / - muscle. In Panel C, the muscle was then evaluated for force loss after repetitive eccentric contraction. Mice combinedly treated with rAAV expressing rAAV.MCK.miR-29c / microdystrophin showed protection from force loss compared to untreated mdx / utrn+ / - muscle (red). Two-way ANOVA. All data represent mean ± SEM (**p<0.01, ****p<0.0001). [Figure 16B] Same as above. [Figure 16C] Same as above. [Figure 17A] The combination therapy shows increased muscle hypertrophy 3 months after injection. Panel A shows rAAV. MCK.miR-29c co-delivered with rAAV expressing microdystrophin did not increase the total weight of injected GAS. Panel B demonstrates that combination therapy with rAAV expressing rAAV.MCK.miR-29c / microdystrophin induced an increase in mean fiber size. Compared to mdx / utrn+ / - controls treated with miR-29c / microdystrophin, mean diameter increased from 28.96 to 36.03 μm. Panel C shows that co-delivery resulted in a shift towards wild-type fiber size distribution. Panel D provides that the number of muscle fibers per 1 mm2 in miR-29c / microdystrophin combination therapy was significantly lower than in untreated mice and wild-type mice (***p<0.01, ****p<0.0001). [Figure 17B] Same as above. [Figure 17C] Same as above. [Figure 17D] Same as above. [Figure 18A]We provide the nucleic acid sequence (SEQ ID NO: 1 pAAV.CMV.Mir29C) of an exemplary rAAV vector containing the maturation guide strand of miR-29c (nucleotides 1257-1284) and the native mi-30 backbone (nucleotides 1088-1375). The construct also contains the CMV promoter (nucleotides 120-526), ​​two EF1a introns at nucleotides 927-1087 and 1380-1854, and polA at nucleotides 1896-2091. [Figure 18B] Same as above. [Figure 19] A schematic diagram of the rAAV vector pAAV.MCK.microdystrophin is provided. [Figure 20A] This document provides the nucleic acid sequence (SEQ ID NO: 9, pAAV.MCK.microdystrophin) of an exemplary rAAV vector expressing microdystrophin. [Figure 20B] Same as above. [Figure 20C] Same as above. [Figure 20D] Same as above. [Figure 21A] This provides the nucleotide sequence of human microdystrophin (SEQ ID NO: 7). [Figure 21B] Same as above. [Figure 21C] Same as above. [Figure 22A] We provide the nucleotide sequence (SEQ ID NO: 12 pAAV.MCK.Mir29C) of an exemplary rAAV vector containing the maturation guide strand of miR-29c (nucleotides 1487-1512) and the native mi-30 backbone (nucleotides 1088-1375). The construct also contains an MCK enhancer (nucleotides 190-395), an MCK promoter (nucleotides 396-753), two EF1a introns at nucleotides 1155-1315 and 1609-2083, and polA at nucleotides 2094-2148. [Figure 22B] Same as above. [Figure 22C] Same as above. [Modes for carrying out the invention]

[0058] The present invention provides a gene therapy vector, such as an rAAV vector, that overexpresses miR-29 microRNA, as well as a method for reducing and preventing fibrosis in patients with muscular dystrophy. The present invention also provides a combination gene therapy comprising administering a gene therapy vector expressing miR-29 in combination with a gene therapy vector expressing deleted microdystrophin in patients with DMD.

[0059] Muscle biopsies taken at the youngest age of diagnosis for DMD reveal significant connective tissue proliferation. Muscle fibrosis is detrimental in several ways. It reduces the normal transport of endomysial nutrients across the connective tissue barrier, decreases blood flow, deprives muscles of blood-derived nutrients, and functionally contributes to early loss of walking due to limb contractures. Over time, the treatment challenge doubles as a result of significant fibrosis in the muscles. This can be observed in muscle biopsies comparing connective tissue proliferation at consecutive points in time. This process continues to worsen, leading to loss of walking and accelerating the uncontrollable progression, especially in patients who are wheelchair dependent.

[0060] Without parallel approaches to mitigate fibrosis, it is unlikely that the full benefits of exon skipping, stop codon read-through, or gene replacement therapy can be achieved. Even small molecule or protein replacement strategies are likely to fail without approaches to mitigate myofibrosis. Previous studies in aged mdx mice with pre-existing fibrosis treated with AAV.microdystrophin showed that complete functional recovery could not be achieved (Human Molecular Genetics 22, 4929-4937 (2013)). Progression of DMD cardiomyopathy is also known to be accompanied by scarring and fibrosis in the ventricular wall. MicroRNA delivery is particularly innovative due to the absence of an immune barrier and relatively easy delivery. MicroRNAs are small (~200 bp) and can therefore be packaged with AAV along with therapeutic cassettes that correct or bypass gene deficiencies.

[0061] As used herein, the term "AAV" is a common abbreviation for adeno-associated virus. Adeno-associated viruses are single-stranded DNA parvoviruses that grow only in cells, provided with certain functions by co-infecting helper viruses. Currently, there are 13 characterized serotypes of AAV. General information and an overview of AAV can be found, for example, in Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169–228, and Berns, 1990, Virology, pp. 1743–1764, Raven Press, (New York). However, since it is well known that various serotypes are very closely related both structurally and functionally, even at the genetic level, it is quite expected that these same principles may apply to additional AAV serotypes. (See, for example, Blacklowe, 1988, pp. 165-174 of Parvoviruses and Human Disease, JR Pattison, ed., and Rose, Comprehensive Virology 3:1-61 (1974)). For example, all AAV serotypes clearly exhibit very similar replication characteristics mediated by homologous rep genes, all of which possess related capsid proteins, such as those expressed in AAV2. The degree of relevance is further suggested by heteroduplex analysis revealing extensive cross-hybridization between genotypes along genome length and the presence of similar self-annealing segments at the terminals corresponding to "reverse terminal repeats" (ITRs). Similar infectivity patterns also suggest that replication function in each serotype is under similar regulatory control.

[0062] As used herein, “AAV vector” refers to one or more target polynucleotides (or transgenes) adjacent to an AAV terminal repeat sequence (ITR). Such AAV vectors can be replicated and packaged into infectious viral particles when present in host cells transfected with vectors encoding and expressing rep and cap gene products.

[0063] An "AAV virion," "AAV virus particle," or "AAV vector particle" refers to a viral particle consisting of at least one AAV capsid protein and a capsid-formed polynucleotide AAV vector. If the particle contains heterologous polynucleotides (i.e., polynucleotides other than the wild-type AAV genome, such as transgenes delivered to mammalian cells), it is typically referred to as an "AAV vector particle" or simply an "AAV vector." Therefore, since such vectors are contained within AAV vector particles, the production of AAV vector particles necessarily involves the production of AAV vectors.

[0064] AAV The recombinant AAV genome of the present invention comprises the nucleic acid molecule of the present invention and one or more AAV ITRs adjacent to the nucleic acid molecule. The AAV DNA in the rAAV genome may be from any AAV serotype from which the recombinant virus may originate, including but not limited to AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, and AAV-13. The generation of pseudotyped rAAV is disclosed, for example, in International Publication No. 01 / 83692. Other types of rAAV variants, such as rAAV with capsid mutations, are also intended. See, for example, Marsic et al., Molecular Therapy, 22(11):1900-1909 (2014). As described in the background section above, nucleotide sequences of genomes of various AAV serotypes are known in the art. AAV1, AAV6, AAV8, or AAVrh.74 can be used to promote skeletal muscle-specific expression.

[0065] The DNA plasmid of the present invention comprises the rAAV genome of the present invention. The DNA plasmid is introduced into a cell tolerant of infection with an AAV helper virus (e.g., adenovirus, E1 deletion adenovirus, or herpesvirus) for the integration of the rAAV genome into infectious viral particles. Techniques for producing rAAV particles in which the AAV genome is packaged, rep and cap genes, and helper virus functions are provided to the cell are standard in the art. The production of rAAV requires that the following components, the rAAV genome, the AAV rep and cap genes isolated from (i.e., not present in) the rAAV genome, and the helper virus functions, be present in a single cell (referred to herein as the packaging cell). The AAV rep and cap genes may be any AAV serotype from which the recombinant virus may originate, and may be from an AAV serotype different from the rAAV genome ITR, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAVrh.74, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, and AAV-13. The generation of pseudotyped rAAV is disclosed, for example, in International Publication No. 01 / 83692, which is incorporated herein by reference in its entirety.

[0066] The method for generating packaging cells involves creating a cell line that stably expresses all the components necessary for AAV particle production. For example, a plasmid (or multiple plasmids) containing an rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes isolated from the rAAV genome, and selectable markers such as neomycin resistance genes, is incorporated into the cell genome. The AAV genome has been introduced into bacterial plasmids by methods such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79:2077-2081), addition of a synthetic linker containing restriction endonuclease cleavage sites (Laughlin et al., 1983, Gene, 23:65-73), or direct blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem., 259:4661-4666). Subsequently, the packaging cell line is infected with a helper virus such as adenovirus. The advantage of this method is that the cells are selectable and it is suitable for large-scale production of rAAV. Another example of a preferred method is to use adenovirus or baculovirus instead of plasmid to introduce the rAAV genome and / or rep and cap genes into the packaging cells.

[0067] The general principles of rAAV production are outlined, for example, in Carter, 1992, Current Opinions in Biotechnology, 1533-539, and Muzyczka, 1992, Curr. Topics in Microbial. and Immunol., 158:97-129). Various approaches are described in Ratschin et al., Mol.Cell.Biol.4:2072(1984), Hermonat et al., Proc.Natl.Acad.Sci.USA,81:6466(1984), Tratschin et al., Mol.Cell.Biol.5:3251(1985), McLaughlin et al., J.Virol.,62:1963(1988), and Lebkowski et al., 1988 Mol.Cell.Biol.,7:349(1988). Samulski et al. (1989, J. Virol., 63:3822-3828), U.S. Patent No. 5,173,414, WO95 / 13365 and corresponding U.S. Patent No. 5,658,776, WO95 / 13392, WO96 / 17947, PCT / US98 / 18600, WO97 / 09441 (PCT / US96 / 14423), WO97 / 08298 (PCT / US96 / 13872), WO97 / 21825 (PCT / US96 / 20777), WO97 / 06243 (PCT / FR96 / 01064), WO99 / 11764, Perrin et al. (1995) Vaccine 13:1244-1250, Paul et al. al. (1993) Human Gene Therapy 4:609-615, Clark et al. (1996) Gene Therapy 3:1124-1132, U.S. Patent No. 5,786,211, U.S. Patent No. 5,871,982, and U.S. Patent No. 6,258,595. The aforementioned documents are incorporated herein by reference in their entirety, with particular emphasis on the portions relating to rAAV production.

[0068] Therefore, the present invention provides packaging cells that produce infectious rAAV. In one embodiment, the packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells, and PerC.6 cells (allogeneic 293 strain). In another embodiment, the packaging cells may be non-transformed cancer cells, such as low-passage 293 cells (human fetal kidney cells transformed with adenovirus E1), MRC-5 cells (human fetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells), and FRhL-2 cells (rhesus monkey fetal lung cells).

[0069] The recombinant AAV (i.e., infectious capsidized rAAV particles) of the present invention comprises an rAAV genome. In exemplary embodiments, the genomes of both rAAVs lack AAV rep and cap DNA, i.e., there is no AAV rep or cap DNA between the ITRs of the genome. An example of an rAAV that can be constructed to contain the nucleic acid molecule of the present invention is described in International Patent Application No. PCT / US2012 / 047999 (WO2013 / 016352), which is incorporated herein by reference in its entirety.

[0070] rAAV can be purified by methods standard in the art, for example, by column chromatography or a cesium chloride gradient. Methods for purifying rAAV vectors from helper viruses are known in the art and include, for example, those disclosed in Clark et al., Hum. Gene Ther., 10(6):1031-1039 (1999), Schenpp and Clark, Methods Mol. Med., 69 427-443 (2002), U.S. Patent No. 6,566,118, and WO98 / 09657.

[0071] In another embodiment, the present invention contemplates a composition comprising the rAAV of the present invention. The composition of the present invention comprises rAAV and a pharmaceutically acceptable carrier. The composition may also contain other components such as diluents and adjuvants. The acceptable carrier, diluent, and adjuvant are non-toxic to the recipient and are preferably inert at the dosages and concentrations used, buffers such as phosphoric acid, citric acid, or other organic acids; antioxidants such as ascorbic acid; proteins such as low molecular weight polypeptides, serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as Tween, pluronics, or polyethylene glycol (PEG).

[0072] The titer of rAAV administered by the method of the present invention varies, for example, depending on the specific rAAV, mode of administration, treatment goal, targeted individual, and cell type(s), and can be determined by standard methods in the art. The titer of rAAV can be about 1×10 6 to about 1×10 7 to about 1×10 8 to about 1×10 9 to about 1×10 10 to about 1×10 11 to about 1×10 12 to about 1×10 13 to about 1×10 14 or more DNase-resistant particles (DRP). The dosage may be expressed in units of viral genome (vg).

[0073] The present invention envisions a method for transducing target cells with rAAV in vivo or in vitro. The in vivo method comprises the step of administering an effective dose or effective multiple dose of a composition comprising rAAV of the present invention to an animal (including humans) in need thereof. If the dose is administered before the onset of the disorder / disease, the administration is prophylactic. If the dose is administered after the onset of the disorder / disease, the administration is therapeutic. In embodiments of the present invention, “effective dose” is a dose that reduces (eliminates or reduces) at least one symptom associated with the disorder / disease condition being treated, slows or prevents progression to the disorder / disease condition, slows or prevents progression to the disorder / disease condition, reduces the severity of the disease, results in disease remission (partial or complete), and / or prolongs survival. An example of a disease envisioned for prevention or treatment by the method of the present invention is FSHD.

[0074] Combination therapy is also intended by the present invention. Combination therapy as used herein includes concurrent and sequential treatments. In particular, combination therapy of the methods of the present invention with standard medical treatments (e.g., corticosteroids), such as in combination with novel therapies, is intended.

[0075] The effective dose of this composition is administered by standard routes in the art, including but not limited to intramuscular, parenteral, intravenous, oral, oral, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal. The administration route(s) and serotype(s) of the AAV components of the rAAV of the present invention (specifically, AAV ITR and capsid protein) may be selected and / or adapted by those skilled in the art, taking into account the infectious disease and / or disease state being treated, as well as the target cells / tissues expressing miR-29 miRNA and / or microdystrophin(s).

[0076] The present invention provides topical and systemic administration of rAAV and compositions of the present invention, including effective doses of the combination therapy of the present invention. For example, systemic administration is administration to the circulatory system so that the entire body is affected. Systemic administration includes enteral administration such as absorption through the gastrointestinal tract and parenteral administration by injection, infusion, or transplantation.

[0077] Specifically, the actual administration of rAAV according to the present invention can be achieved by using any physical method to deliver the rAAV recombinant vector to the target tissue of an animal. Administration according to the present invention includes, but is not limited to, intramuscular injection, bloodstream injection, and / or direct hepatic injection. It has been demonstrated that simply resuspending rAAV in phosphate-buffered saline is sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on carriers or other components that may be co-administered with rAAV (however, compositions that degrade DNA should be avoided in the usual manner with rAAV). The capsid protein of rAAV may be modified so that rAAV targets a specific target tissue of interest, such as muscle. See, for example, WO02 / 053703, the disclosure of which is incorporated herein by reference. Pharmaceutical compositions may be prepared as injectable formulations or as topical formulations delivered to muscle by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and may be used in carrying out the present invention. rAAV may be used with any pharmaceutically acceptable carrier for ease of administration and handling.

[0078] The dose of rAAV administered by the methods disclosed herein may vary depending, for example, on the specific rAAV, mode of administration, therapeutic target, target organism, and cell type(s), and may be determined by standard methods in the art. The titer of each rAAV administered may range from approximately 1 × 10⁶, 1 × 10⁷, 1 × 10⁸, 1 × 10⁹, 1 × 10¹⁰, 1 × 10¹⁰, 1 × 10¹¹, 1 × 10¹², 1 × 10¹³, 1 × 10¹⁴, or 1 × 10¹⁵ or more DNase-resistant particles (DRPs) per ml. The dosage is measured in units of viral genome (vg) (i.e., 1 × 10¹⁰ each). 7 vg, 1x10 8 vg, 1x10 9 vg, 1x10 10 vg, 1x10 11 vg, 1x10 12 vg, 1x10 13 vg, 1x1014 vg, 1×10 15 The dosage may be expressed in units of viral genomes (vg) per kilogram (kg) of body weight (i.e., 1 x 10⁻¹⁶ units). 10 vg / kg, 1x10 11 vg / kg, 1x10 12 vg / kg, 1x10 13 vg / kg, 1x10 14 vg / kg, 1 × 10 15 It may also be expressed in vg / kg. The method for titrating AAV is described in Clark et al., Hum. Gene Ther., 10:1031-1039 (1999).

[0079] Specifically, the actual administration of rAAV according to the present invention can be achieved by using any physical method to deliver the rAAV recombinant vector to the target tissue of an animal. Administration according to the present invention includes, but is not limited to, intramuscular injection, bloodstream injection, and / or direct hepatic injection. It has been demonstrated that simply resuspending rAAV in phosphate-buffered saline is sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on carriers or other components that may be co-administered with rAAV (however, compositions that degrade DNA should be avoided in the usual manner with rAAV). The capsid protein of rAAV may be modified so that rAAV targets a specific target tissue of interest, such as muscle. See, for example, WO02 / 053703, the disclosure of which is incorporated herein by reference. Pharmaceutical compositions may be prepared as injectable formulations or as topical formulations delivered to muscle by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and may be used in carrying out the present invention. rAAV may be used with any pharmaceutically acceptable carrier for ease of administration and handling.

[0080] For intramuscular injection purposes, solutions in adjuvants such as sesame oil or peanut oil, or in aqueous propylene glycol, as well as sterile aqueous solutions, may be used. Such aqueous solutions are buffered if desired, and the liquid diluent is first made isotonic with physiological saline or glucose. rAAV solutions as free acids (DNA containing acidic phosphate groups) or pharmacokinetically acceptable salts can be prepared in water suitably mixed with a surfactant such as hydroxypropyl cellulose. rAAV dispersants can be prepared in glycerol, liquid polyethylene glycol, and mixtures thereof, as well as in oil. Under normal storage and use conditions, these preparations contain preservatives to inhibit microbial growth. In this regard, all sterile aqueous media used can be readily obtained by standard techniques well known to those skilled in the art.

[0081] Suitable pharmaceutical carriers, diluents, or excipients for injectable use include sterile aqueous solutions or dispersants, and sterile powders for the immediate preparation of injectable sterile solutions or dispersants. In all cases, this form must be sterile and fluid enough to allow for easy syringe injection. It must be stable under manufacturing and storage conditions and protected against contamination by microorganisms such as bacteria and fungi. Carriers may be solvents or dispersion media containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. Adequate fluidity can be maintained, for example, by the use of coatings such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. Protection against microbial action can be provided by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. It is often preferable to include isotonic agents, such as sugars or sodium chloride. Long-term absorption of injectable compositions can be achieved by using absorption-delaying agents, such as aluminum monostearate and gelatin.

[0082] Injectable sterile solutions are prepared by incorporating the required amount of rAAV, if necessary, into a suitable solvent containing various other components listed above, and then sterilizing by filtration. Generally, dispersants are prepared by incorporating the sterile active ingredient into a sterile vehicle containing a basic dispersion medium and other necessary components from those listed above. For sterile powders for the preparation of injectable sterile solutions, preferred preparation methods are vacuum drying and freeze-drying techniques, which produce powders of the active ingredient plus any additional desired components from its previously sterile filtered solution.

[0083] Transduction with rAAV can also be performed in vitro. In one embodiment, desired target muscle cells are removed from the subject, transduced with rAAV, and reintroduced into the subject. Alternatively, syngeneic or heterogeneic muscle cells may be used if they do not produce an inappropriate immune response in the subject.

[0084] Suitable methods for transduction and reintroduction of transduced cells into a target are known in the art. In one embodiment, cells can be transduced in vitro, for example, by combining rAAV with muscle cells in a suitable culture medium and screening for cells with the desired DNA using conventional techniques such as Southern blotting and / or PCR, or by using a selectable marker. The transduced cells can then be formulated into a pharmaceutical composition, which is introduced into a target by various techniques such as intramuscular, intravenous, subcutaneous, and intraperitoneal injection, or by injection into smooth myocardium, for example, using a catheter.

[0085] Transduction of cells in rAAV according to the present invention results in sustained expression of miR-29 or microdystrophin. Accordingly, the present invention provides a method for administering / delivering rAAV expressing miR-29 and / or microdystrophin to animals, preferably humans. These methods include transducing tissues in one or more rAAVs according to the present invention (including, but not limited to, tissues such as muscle, organs such as liver and brain, and glands such as salivary glands). Transduction may be carried out with a gene cassette containing tissue-specific regulatory elements. For example, one embodiment of the present invention is not limited to those described above, but includes those derived from the actin and myosin gene families, such as the myoD gene family [see Weintraub et al., Science, 251:761-766 (1991)], muscle cell-specific enhancer binding factor MEF-2 [Cserjesi and Olson, Mol. Cell. Biol., 11:4854-4862 (1991)], human skeletal muscle actin gene [Muscat et al., Mol. Cell. Biol., 7:4089-4099 (1987)], cardiac muscle actin gene, muscle creatine kinase sequence elements [Johnson et al.]. The present invention provides a method for transducing muscle cells and muscle tissue induced by muscle-specific regulatory elements, including regulatory elements derived from mouse creatine kinase enhancer (mCK) elements, regulatory elements derived from skeletal fast-twitch muscle troponin C gene, slow-twitch muscle cardiac troponin C gene, and slow-twitch muscle troponin I gene: hypoxia-induced nuclear factor (Semenza et al., Proc. Natl. Acad. Sci. USA, 88:5680-5684 (1991)), steroid-induced elements, and promoters containing glucocorticoid response elements (GRE) (see Mader and White, Proc. Natl. Acad. Sci. USA, 90:5603-5607 (1993)), as well as other regulatory elements.

[0086] Muscle tissue is an attractive target for in vivo DNA delivery because it is not a vital organ and is easily accessible. This invention aims to achieve sustained expression of transduced myofibrils-derived miRNAs.

[0087] "Muscle cells" or "muscle tissue" means cells or groups of cells derived from any type of muscle (e.g., skeletal muscle and smooth muscle, derived from the digestive tract, bladder, blood vessels, or cardiac tissue). Such muscle cells may be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes, and cardiomyocytes.

[0088] The term "transduction" is used to refer to the administration / delivery of the miiR29 guide chain or microdystrophin coding region to recipient cells, either in vivo or in vitro, via the replication-deficient rAAV of the present invention, resulting in the expression of miR29 or microdystrophin by the recipient cells.

[0089] Therefore, the present invention provides a method for administering an effective dose (or a dose essentially administered simultaneously or at intervals) of rAAV encoding miR29 and / or microdystrophin to a patient in need. [Examples]

[0090] Example 1 Confirmation of the Duchenne muscular dystrophy model The mdx mouse provides a convenient but still incomplete animal model for studying the pathogenesis of DMD. This model is a cross between an mdx mouse and a heterozygous knockout of the eutrophin gene (mdx:utrn+ / -), exhibiting increased fibrosis and more faithfully reproducing the pathology of human DMD. Mdx mice have a nonsense mutation in exon 23 of DMD, resulting in a relatively mild phenotype and nearly normal lifespan. By 3 weeks of age, the diaphragm and limb muscles of mdx mice show signs of endomysitis. These symptoms subside in the limb muscles after the mouse reaches adulthood, but inflammation in the diaphragm muscles continues to gradually worsen. In telomerase-deficient mdx mice, muscular dystrophy gradually worsens with age, and eutrophin-deficient mdx mice (DKO) exhibit a phenotype more characteristic of human DMD, with early-onset muscle weakness, severe fibrosis, and early death. Eutrophin, an autosomal paralog of dystrophin, shares a high degree of sequence homology that can compensate for the absence of dystrophin in double knockout (dystrophin + eutrophin) mdx mice, resulting in a severe phenotype accompanied by early death. Early death in DKO mice eliminates the progression of inflammation and fibrosis, but mdx:utrn + / - The mouse model presents a model with similarities to the human disease, exhibiting a significant degree of fibrosis and a longer survival period than DKO, providing a better model for proposed conversion studies. Recent reports suggest mdx:utrn + / - The use of mice has been confirmed as an ideal model for studying fibrosis in association with DMD. In this study, increased fibrosis, as measured by Sirius Red staining, was accompanied by increased collagen transcript levels and decreased mir29c levels.

[0091] Example 2 Delivery of miR29 to DMD mice reduces fibrosis. The preliminary study involved human DMD patients and mdx / utrn + / -In mice, we have demonstrated a significant increase in Sirius Red staining for collagen and a decrease in miR-29c levels. Gene delivery of miR-29 using muscle-specific AAV vectors is potentially safe and efficient. To generate the rAAV vector referred to herein as rAAVrh.74.CMV.miR29c, a 22-nucleotide miR29c sequence (target chain SEQ ID NO: 3 and guide chain SEQ ID NO: 4) was cloned into a miR-30 scaffold driven by a CMV promoter. The expression cassette (SEQ ID NO: 2) was cloned into a self-complementary AAV plasmid and packaged using serotype AAVrh.74, which is known to be well expressed in muscle. miR-29c cDNA was synthesized using custom primers containing a miR-30c target (sense) strand, a miR-30 stem-loop, and a miR-29c guide (antisense) strand on a miR-30 backbone. Three bases of the miR-29c sequence were modified. Next, this sequence was cloned into a self-complementary AAV ITR-containing plasmid driven by a CMV promoter and a poly(A) sequence.

[0092] As shown in Figure 1, the pAAV.CMV.miR29C plasmid contains mir29c cDNA in the miR-30 stem-loop backbone adjacent to the AAV2 reverse terminal repeat (ITR). This sequence was capsidized to AAVrh.74 virion. Furthermore, several nucleotides within the miR-29c target sequence were modified to mimic the Watson-Crick pairing at this site, similar to shRNA-miR(luc). Following the shRNA-luc design, the hairpin must be perfectly complementary throughout its entire length. In addition, the more modifications made to the passenger strand, the higher the likelihood of eliminating the endogenous mechanism that regulates miR-29 processing, enabling miRNA recognition via the stem. The 19th base of the guide strand was modified to cytosine to mimic the nucleotide preceding the cleavage site in the natural mi-29c sequence, and the corresponding base on the other strand was modified to preserve the pairing.

[0093] Gene therapy vector scrAAVrh.74.CMV.miR29c(1×10) 11 (vg) 3-month-old MDX / UTRN + / - The drug was injected into the quadriceps muscles of mice. The quadriceps muscles were analyzed 3 months after injection using Sirius Red staining and then analyzed using NIH ImageJ software as described in Nevo et al. (PloS One, 6:e18049 (2011)). MiR29c, collagen, and elastin levels were quantified by RT-PCR. (Young mdx / utrn) + / - Delivery of miR-29c to mice was performed using 6-month-old mdx / utrn mice. + / - In mice (3 months after injection), the treatment significantly increased mir-29c levels and significantly decreased Sirius Red staining in the quadriceps muscle. RT-PCR evaluation revealed a decrease in collagen and elastin levels in the treated muscle.

[0094] mdx / utrn + / - Demonstrating increased fibrosis and decreased miR29 expression in mice and dystrophin-deficient patients confirms the effectiveness of the mouse model as a representative of human disease. Early results using miR29 delivered via AAV as an anti-fibrotic therapy suggest a significant beneficial effect on Sirius red staining and decreased collagen and elastin levels, which are key factors in fibrosis.

[0095] Example 3 MiR-29c injections reduce collagen and restore miR-29c levels. To determine if rAAVrh.74.CMV.MiR-29c can alleviate fibrosis, we used mdx / utrn in 12-week-old infants. +￥- The mouse had 5x10 units of injection into the left gastrocnemius (GAS) muscle. 11The mice received intramuscular injections of vg rAAVrh.74.CMV.MiR-29c. Mice were analyzed 12 weeks after injection. Piclosirius red staining revealed a significant decrease in collagen staining throughout the GAS muscle (Figure 2a) compared to untreated contralateral mdx / utrn+ / - GAS muscle. Quantification of picrosirius red staining showed that the treated muscle had an 18.3% decrease in collagen compared to untreated muscle (treated -23.3%±1.3 vs. untreated -29.5%±0.7) (Figure 2b). To confirm the overexpression of miR-29c in the treated muscle, 24-week-old WT, miR-29c-treated mice, and mdx / utrn mice were used. + / - Total RNA was extracted from GAS muscle tissue of mice and subjected to quantitative reverse transcription PCR (qRT-PCR) analysis for miR-29c expression. The results showed a significant increase in miR-29c in GAS muscle tissue of treated mice compared to untreated mice (Figure 2d).

[0096] Example 4 MiR-29c improves absolute and specific muscle strength, but does not protect against contraction-induced injury. Since it is known that fibrosis can affect muscle function, increasing MiR-29c expression may reduce fibrosis and prevent contraction-induced injury. + / - I wanted to test whether it would protect the muscles and increase overall strength. The patient was treated with rAAVrh.74.CMV.MiR-29c mdx / utrn. + / - The functional characteristics of the gastrocnemius muscle from mice were evaluated. Twelve weeks after injection, gastrocnemius stenosis (GAS) was isolated and in vivo force measurements were performed.

[0097] The GAS procedure follows the protocol enumerated by Hakim et al. (Methods Mol Biol. 709:75-89, 2011) for analyzing the physiology of the transverse abdominal muscle, but adapted for GAS. Briefly, mice were anesthetized with a ketamine / xylazine mixture. The skin of the hind limbs was removed to expose the GAS muscle and Achilles tendon. The distal tendon was excised, and a 4-0 suture was double-knotted around the tendon as close to the muscle as possible, another second double-knot was made immediately next to the first knot, and then the tendon was cut. The exposed muscle was kept moist with saline solution at all times. The mice were then transferred to a heat-controlled platform and maintained at 37°C. The knee was fixed to the platform with a needle through the patellar tendon, the tendon was sutured to the level arm of a force transducer (Aurora Scientific, Aurora, ON, Canada), and the foot was secured with tape. GAS muscle contraction was induced by stimulating the sciatic nerve via bipolar platinum electrodes. Once the muscle was stabilized, the optimal length was determined by gradually lengthening the muscle until maximum contractile force was achieved. After a 3-minute rest period, the GAS muscle was stimulated at 50, 100, 150, and 200 Hz with a 1-minute rest period between each stimulus to determine the maximum tetanic force. The muscle length was measured. After a 5-minute rest period, the sensitivity of the GAS muscle to contraction-induced injury was assessed. After 500 ms of stimulation, the muscle lengthened by 10% of its optimal length. This consisted of stimulating the muscle at 150 Hz for 700 ms. After stimulation, the muscle returned to its optimal length. This cycle was repeated for a total of 5 cycles at 1-minute intervals. Specific force was calculated by dividing the maximum tetanic force by the cross-sectional area of ​​the GAS muscle. After eccentric contraction, the mice were then euthanized, the GAS muscle was excised, weighed, and frozen for analysis.

[0098] Each GAS underwent a series of repetitive eccentric contractions. By comparing the force ratio of each contraction to the first contraction, it was found that after the fifth contraction, the untreated muscle attenuated to 0.56±0.05 compared to the treated muscle (0.50±0.04) (P≦0.0001). The injected group showed a slight decrease in the degree of protection compared to the WT control, which attenuated to 0.92±0.02 (Figure 3c). These data suggest that reducing fibrosis by increasing miR-29c expression increases both absolute and specific force, but does not significantly protect the muscle from contraction-induced injury.

[0099] rAAVrh.74.MiR-29c treated GAS muscle, untreated mdx / utrn + / - It showed a significant improvement in absolute strength compared to the GAS muscle (rAAV.miR-29c-2277±161.7 vs mdx / utrn). + / - Untreated -1722±145.7 (Figure 3a), and compared to untreated GAS muscle, rAAV.74.miR-29c normalized the specific strength in GAS muscle-specific improvement (rAAV.miR-29c -204.7±11.7 vs. mdx / utrn). + / - Untreated -151.6±14.5 (Figure 3b). Compared to wild-type controls, strength remained significantly reduced (rAAV.miR-29c-204.7±11.7 vs. wild-type -312.0±34.1).

[0100] Example 5 Co-delivery with microdystrophin further alleviates fibrosis. To determine whether the miR-29c / microdystrophin combination gene therapy approach is more beneficial in alleviating fibrosis, we used a 12-week-old MDX / UTRN gene therapy approach. +￥- The mouse had 5x10 stimuli in its left calf muscle. 11 The patient received an intramuscular injection of vg rAAVrh.74.CMV.MiR-29c. The following gene therapy vectors were administered: scAAVrh.74.CMV.miR-29c alone, co-delivered with rAAVrh.74.MCK.microdystrophin, and rAAVrh.74.MCK.microdystrophin alone to a 3-month-old mdx / utrn. + / -The drug was administered by intramuscular injection (IM) into the left gastrocnemius (GAS) muscle of a mouse and DMD mouse model.

[0101] The pAAV.MCK.microdystrophin plasmid contains a human microdystrophin cDNA expression cassette adjacent to the AAV2 reverse terminal repeat (ITR), as shown in Figure 10. This sequence was capsidized to AAVrh.74 virion. The pAAV.MCK.microdystrophin plasmid was constructed by inserting an MCK expression cassette driving a codon-optimized human microdystrophin cDNA sequence into an AAV cloning vector, as described by Rodino-Klapac et al. (Mol Ther. 2010 Jan;18(1):109-17). The MCK promoter / enhancer sequence was used to drive muscle-specific gene expression and consists of a mouse MCK core enhancer (206 bp) fused to a 351 bp MCK core promoter (proximal). Following the core promoter, a 53 bp endogenous mouse MCK Exon 1 (untranslated) is present for efficient transcription initiation, followed by a late SV40 16S / 19S splice signal (97 bp) and a small 5' UTR (61 bp). The intron and 5' UTR are derived from plasmid pCMVβ (Clontech). The microdystrophin cassette has a consensus Kozak and a small 53 bp synthetic poly(A) signal for mRNA termination immediately before the ATG initiation. The human microdystrophin cassette contains a (R4-R23 / Δ71-78) domain. Complementary DNA was codon-optimized for human use and synthesized by GenScript (Piscataway, NJ).

[0102] Mice were analyzed 12 and 24 weeks after injection. First, the effectiveness of transgene delivery was evaluated using the number of muscle fibers expressing microdystrophin, ensuring that similar levels of microdystrophin expression were achieved in each group. Microdystrophin levels were found to be similar between the cohorts treated with miR-29c / microdystrophin combination therapy (75.03 ± 1.91%) and those treated with microdystrophin alone (71.85 ± 2.25%) (Figure 4).

[0103] GAS muscle was analyzed 12 months after injection, and collagen accumulation was assessed by Sirius Red staining and subsequent quantification in ImageJ. Further results included miR-29c and collagen transcript levels, force measurements in GAS muscle, fiber diameter measurements, and Western blot analysis of proteins involved in muscle regeneration (MyoD, myogenin). The amount of fibrosis was analyzed by picrosirius red staining, revealing a significant decrease in collagen staining throughout the GAS muscle in all treatment groups compared to untreated contralateral mdx / utrn+ / - GAS muscle or microdystrophin alone (Figure 5a). Quantification of picrosirius red staining showed that combination-treated muscle had a 40.8% decrease in collagen compared to untreated muscle (treated -17.47%±0.75 vs. untreated -29.5%±0.7) (Figure 5b). To confirm miR-29c expression, qRT-PCR was performed on GAS muscle, and all treatment groups showed an increase in miR-29c compared to untreated muscle (Figure 5c).

[0104] Similar to the DMD organization, mdx / utrn + / -A significant decrease in miR-29c levels was observed in muscle tissue, correlating with an increase in fibrosis as measured by picrosilius red staining. Three months after treatment with scAAV.miR-29c alone, there was a significant reduction in fibrosis in GAS muscle (treated -23.5%±1.3 vs. untreated -27.8%±0.6). When co-delivered with microdystrophin, a further decrease in collagen (41%) was observed by picrosilius red staining (combination treatment: 17.47%±0.75 vs. untreated: 29.5%±0.7) (p<0.0001) (Figure 5b). To confirm miR-29c expression, qRT-PCR was performed in GAS muscle, and all treatment groups had increased miR-29c compared to untreated muscle (Figure 5b).

[0105] 24 weeks after injection, the results were similar to those observed 12 weeks after injection. Compared to untreated muscle, there was a 47% decrease in collagen as measured by picrosilius red staining (combination therapy: 16.5±1.23 vs. untreated: 31.07±0.93, p<0.0001) and, simultaneously, an increase in miR-29c transcript levels.

[0106] To further investigate the collagen reduction observed by picrosilius red staining, qRT-PCR was performed in muscle to quantify transcript levels of Col1A, Col3A, and another ECM component, fibronectin (Fbn). qRT-PCR analysis detected decreases in Col1A and Col3A after each treatment, but only the cohort treated with both microdystrophin and miR-29c showed a significant decrease (Figures 6a and 6b). The analysis revealed that Fbn was significantly reduced only in the combination therapy cohort (Figure 6c).

[0107] TGF-β1 has previously been shown to be upregulated in dystrophy muscle and is likely involved in the initiation of the fibrosis cascade. TGF-β1 is a known pro-fibrosis cytokine that downregulates miR-29c and is responsible for the conversion of myoblasts to myofibroblasts, leading to increased collagen and muscle fiber formation. qRT-PCR analysis showed that combination-treated muscle had significantly lower levels of TGF-β1 compared to uninjected muscle and muscle treated with either monotherapy (Figure 6d). Six months after injection, combination-treated muscle continued to show decreased Col1A, Col3A, Fbn, and TGF-β1 levels, while only a slight decrease in Col1A mRNA levels was observed in the miR-29 and microdystrophin-only groups.

[0108] Compared to untreated limbs, muscles treated with miR-29c alone showed increases in specific and absolute force, and when combined with microdystrophin, it resulted in absolute and specific force that were not significantly different from wild-type muscles. Furthermore, a significant increase in gastrocnemius muscle weight was observed in muscles treated with this combination therapy.

[0109] Initial results from using rAAV.miR-29c as an anti-fibrotic therapy suggest a beneficial effect on the reduction of collagen levels, a major cause of fibrosis. Furthermore, when combined with microdystrophin to improve membrane stability, miR29 upregulation normalized muscle strength.

[0110] Example 6 Further increase in absolute force and added protection against contraction-induced injury. Since miR-29-treated muscles were found to have a modest but significant increase in absolute and specific force, the effects of combination therapy with miR-29c overexpression and microdystrophin gene substitution on muscle function were investigated. Twelve weeks after injection, GAS was isolated and in vivo force measurements were performed. The rAAVrh.74.MiR-29c vector and rAAV described above in Example 2 were used.

[0111] GAS muscle treated with combination therapy with rAAVrh.74.MiR-29c and rAAV expressing microdys was compared to untreated mdx / utrn + / - Compared to GAS muscle, it showed a significant improvement in absolute strength (combined treatment -3582.4±79.4nM vs. mdx / utrn). + / - Untreated -1722±145.7nM vs. wild-type -3005±167.3nM) (Figure 7), and the specific improvement in rAAVrh.74.miR-29c / microdis treated GAS muscle compared to untreated GAS muscle normalized the specific strength (combination-treated mice -244.2±6.6nM / mm²). 2 vs mdx / utrn + / - Untreated -151.6±14.5nM / mm 2 Ratio: 312.0 ± 34.1 nM / mm 2 (Figure 7). There were no significant differences in either absolute force or specific force compared to the wild-type control.

[0112] Each GAS underwent a series of repetitive eccentric contractions. By comparing the force ratio of each contraction to the first contraction, it was found that after the fifth contraction, untreated muscle attenuated to 0.54±0.06 compared to 0.66±0.04 with combination therapy (P≦0.0001), and since microdystrophin alone also attenuated to 0.66±0.04, this may be attributable to microdystrophin. The treated group remained significantly lower than the wild-type group, which attenuated to 0.92±0.02 (Figure 7c). Similar findings were observed 24 weeks after injection. These data suggest that fibrosis reduction and gene replacement increase both absolute and specific force and significantly protect muscle from contraction-induced injury.

[0113] Example 7 Combination therapy increases muscle hypertrophy and hyperplasia. MiR-29c, delivered co-administered with microdystrophin, increased the total weight of the injected gastrocnemius muscle compared to either administered alone at 3 months of age (Figures 8 and 9a). To investigate the cause of the increased muscle mass, muscle fiber diameter was measured. MiR-29c / μ-dys combination therapy showed an increase in mean fiber size. + / -Control group: miR-29c / μ-dys treatment mdx / utrn + / - In comparison, the average diameter increased from 25.96 to 30.97 μm (Figure 9b). Co-delivery resulted in a shift towards the wild-type fiber size distribution (Figure 9c). Although the average fiber size increased, this does not explain the ~30% increase in total muscle weight. Total muscle cross-sectional area was also measured. Gastrocnemius muscles from all groups were full-slide scans and total area was measured. Muscles treated in combination with Microdis / miR-29c had a significant increase in cross-sectional area compared to untreated and mono-treated (uninjected: 24.6 vs. miR-29c: 26.3 vs. Microdis: 26.6 vs. Microdis / miR-29c: 33.1) (Figures 8, 9d).

[0114] miR-29c has been reported to play a role in the myoD / Pax7 / myogenin pathway, and it was hypothesized that miR-29c may influence the regeneration and activation of satellite cells (muscle stem cells) differentiating in the myogenic lineage. To test this, the total number of muscle fibers from full-slide scan images was counted. Increase in the number of muscle fibers after miR-29c / μ-dys combination therapy (Figure 9e). Finally, considering that the muscle fiber diameter in mdx / utrn+ / - mice differs from that of many small-diameter fibers and some hypertrophic fibers, it was determined whether the number of fibers per unit area (cells / mm2) was affected by the treatment. The miR-29c / μ-dys combination therapy was no different from the wild type (Figure 9f).

[0115] Example 8 Early combination therapy prevents fibrosis. Considering the potential importance of combinatorial miR-29c and microdystrophin as prophylactic therapies for DMD, younger MDX / UTRN + / -A cohort of mice was treated at 4 weeks of age. Using the same paradigm as the other groups described herein, the following treatments were compared for the efficacy of intramuscular injection of GAS for fibrosis prevention: the same dose of scAAVrh.74.CMV.miR-29c alone, ssAAVrh74.MCK.microdystrophin + scAAVrh74.CMV.miR-29c combination therapy, or ssAAVrh74.MCK.microdystrophin alone. Mice were necropsied 12 weeks after injection. Untreated contralateral mdx / utrn + / - Compared to GAS muscle, a significant decrease in collagen staining throughout the GAS muscle was observed in all treated groups (Figure 10A). Quantification of picrosilius red staining showed that muscle treated with microdystrophin / miR-29c had a 51% decrease in collagen compared to untreated muscle (treated -11.32%±1.18 vs. untreated -23.15%±0.90) (p<0.0001) (Figure 10), and pRT-PCR confirmed decreases in Col1A, Col3A, Fbn, and TGF-β1 after combinatorial therapy (Figures 10D and E).

[0116] Example 9 Early combination therapy leads to better strength recovery and protection against contraction-induced injury than later treatment. In vivo measurements were performed on GAS in mice treated early with combination therapy as described in Example 8. (4-week-old mdx / utrn) + / - In mice, combination therapy with miR-29c / microdystrophin was effective against untreated mdx / utrn + / - Compared to mice, the mice showed a significant improvement in absolute force, with no difference compared to the wild type (combination therapy: 2908±129.5 mN vs. untreated: 1639.4±116.9 mN vs. wild type: 3369.73±154.1 mN). Specific force also normalized to wild-type levels after combinatorial therapy (combination therapy: 338.9±22.34 mN / mm² vs. untreated: 184.3±13.42 mN / mm²). 2 Relative to WT364.3±7.79mN / mm 2 (Figures 11A, 11B, and 12).

[0117] Next, each GAS underwent a series of repetitive eccentric contractions. By comparing the force ratio of each contraction after the fifth contraction, the untreated muscle was attenuated to 0.53±0.04 compared to 0.82±0.04 in the combination treatment group (P≦0.0001). The combinational treatment group was slightly lower than the wild type, attenuated to 0.93±0.01, but the difference was not significant (Figure 11C). These data suggest that fibrosis reduction and gene replacement increase both absolute and specific force and significantly protect the muscle from contraction-induced injury.

[0118] These experiments suggest that gene replacement should be initiated in the neonatal period. Efforts are clearly moving towards identifying DMD and other muscular dystrophy in the neonatal period. The Ohio Newborn Screening Study demonstrates the potential for identifying DMD in newborns using CK 7 Neurol. as a biomarker (>2000 U / L) with DNA confirmation on the same dried blood spot (Mendell et al., Ann. Neurol. 71:304-313, 2012). This methodology is now being expanded in the United States (PPMD, May 16, 2016: Next Steps with Newborn Screening) and other countries, particularly the United Kingdom (UK National Screening Committee) and China (Perkin Elmer® has launched screening in China).

[0119] miR-29 has also shown promise as a therapeutic modality for cardiac, pulmonary, and hepatic fibrosis. Myocardial infarction in mice and humans is associated with miR-29 downregulation. Rooij et al. (Proc. Natl. Acad. Sci, USA 105:13027-13032, 2008) demonstrated that exposure of fibroblasts to a miR-29b mimite reduced collagen transcripts and provided a pathway for clinical transformation of cardiac fibrosis. Subsequent studies have shown that fibrosis attenuation can be achieved in a mouse model of bleomycin-induced pulmonary fibrosis using delivery of miR-29b based on the Sleeping Beauty (SB) transposon system.14 Currently, the miR-29b mimite is in a clinical Phase 1 Safety-Tolerability topical transdermal study in healthy volunteers (miRagen Therapeutics® MRG-201). Compared to miR-29 oligonucleotide delivery, which requires repeated dosing due to the half-life of the oligonucleotides, AAV gene therapy may potentially offer a pathway for single-delivery gene transfer.

[0120] Example 10 Treatment with muscle-specific expression of miR-29 and microdystrophin reduced fibrosis and ECM expression. An AAV vector containing the miR29c sequence and the muscle-specific promoter MCK was also generated and tested as a combination therapy with an AAV vector expressing microdystrophin. To generate the rAAV vector referred to herein as rAAV.MCK.miR29c, the 22-nucleotide miR29c sequence (target chain SEQ ID NO: 3 and guide chain SEQ ID NO: 4) was cloned into a miR-30 scaffold (SEQ ID NO: 11) driven by the MCK promoter. The expression cassette (SEQ ID NO: 12) was cloned into a single-stranded AAV plasmid and packaged using serotype AAVrh74, which is known to be well expressed in muscle. miR-29c cDNA was synthesized using custom primers containing a miR-30 backbone, a miR-30c target (sense) strand, a miR-30 stem-loop, and a miR-29c guide (antisense) strand. Three bases of the miR-29c sequence were modified. Next, this sequence was cloned into a single-stranded AAV ITR-containing plasmid driven by an MCK promoter and a poly(A) sequence.

[0121] The pAAV.MCK.miR29C plasmid contains mir29c cDNA in the miR-30 stem-loop backbone adjacent to the AAV2 reverse terminal repeat (ITR). This sequence was capsidized to the AAVrh74 virion. Furthermore, several nucleotides within the miR-29c target sequence were modified to mimic the Watson-Crick pairing at this site, similar to shRNA-miR(luc). Following the shRNA-luc design, the hairpin must be perfectly complementary throughout its entire length. In addition, more changes to the passenger strand may eliminate the endogenous mechanism that regulates miR-29 processing, enabling miRNA recognition via the stem. The 19th base of the guide strand was modified to cytosine to mimic the nucleotide preceding the cleavage site in the natural mi-29c sequence, and the corresponding base on the other strand was modified to preserve the pairing.

[0122] Early treatment with AAV.MCK.miR-29c / microdystrophin combination therapy was more effective in reducing fibrosis and ECM development. (mdx / utrn at 4-5 weeks of age) +￥- The mouse was subjected to 5x10 injections in the left calf muscle, as described in Example 5. 11 Vg mice received intramuscular injections of rAAVrh.74.MCK.MiR-29c and rAAVrh74.MCK.microdystrophin. Muscle tissue was collected 12 weeks after injection. Piclosilius red staining of muscle tissue collected from uninjected mice and mice injected with combination therapy of rAAV.MCK.miR-29c / rAAV.MCK.microdystrophin showed that the combination-treated muscle tissue had a 50.9% decrease in collagen compared to the untreated GAS muscle tissue (see Figures 13a and 13b), and qRT-PCR confirmed an increase in miR-29c transcript levels in the treated cohort (Figure 13c). Semi-quantitative qRT-PCR showed significant reductions in collagen 1A and collagen 3A (Figure 13d, e), fibronectin (Figure 13f), and Tgfβ1 (Figure 13g) levels in AAV.MCK.miR-29c / AAV.microdystrophin-treated muscles compared to contralateral limb therapy (*p<0.05,****p<0.0001). Late-stage AAV.MCK.miR-29c / microdystrophin combination therapy is effective in reducing fibrosis and ECM development. (mdx / utrn at 3 months of age) +￥- The mouse was subjected to 5x10 injections in the left calf muscle, as described in Example 5. 11Intramuscular injections of rAAVrh.74.MCK.MiR-29c and rAAVrh.74.MCK.microdystrophin were administered to vg limbs. Muscle tissue was harvested 12 weeks after injection. Piclosilius red staining of untreated, AAV.MCK.miR-29c, and AAV.MCK.miR-29c / AAV.microdystrophin-treated muscles showed a 30.3% decrease in collagen in the combination-treated muscles compared to the untreated GAS muscles (see Figures 14a and 14b), and qRT-PCR confirmed increased miR-29c transcript levels in the treated cohort (Figure 14c). Semi-quantitative qRT-PCR showed significant decreases in collagen 1A and collagen 3A (Figures 14d, e), fibronectin (Figure 14f), and Tgfβ1 (Figure 14g) levels in AAV.miR-29c / AAV.microdystrophin-treated muscles compared to the contralateral limb. One-way ANOVA. All data represent mean ± SEM. (**p<0.01, ****p<0.0001).

[0123] Example 11 Early combination therapy leads to better strength recovery and protection against contraction-induced injury than later treatment. In vivo measurements were performed on GAS in mice treated early with muscle-specific expression of miR-29 and microdystrophin, as described in Examples 8 and 9. (4-week-old mdx / utrn) + / - In mice, combination therapy using rAAV.MCK.miR-29c / and rAAV expressing microdystrophin was effective in treating untreated mdx / utrn + / - Compared to mice, the mice showed a significant improvement in absolute strength, with no difference compared to the wild type (Figure 15a). Specific strength also normalized to wild-type levels after combination therapy (Figure 15b).

[0124] The muscles were then evaluated for force loss after repetitive eccentric contractions, as described in Example 9. Mice treated in combination with rAAV.miR-29c / rAAV.MCK.microdystrophin and mice treated with rAAV.MCK.microdystrophin monotherapy were compared with untreated mdx / utrn. +￥-It showed protection against force loss compared to muscle (Figure 15c).

[0125] 12-week-old MDX / UTRN + / - In mice, combination therapy with rAAV expressing rAAV.MCK.miR-29c / and microdystrophin restored strength and protected against contraction-induced injury. Absolute force (Figure 16a) and normalized specific force (Figure 16b) after tetanic contraction were measured in GAS muscles injected with rAAV expressing rAAV.MCK.miR-29c and microdystrophin, compared to untreated mdx / utrn. + / - Compared to muscle, there was a significant increase. Subsequently, muscle was evaluated for force loss after repetitive eccentric contractions, as described in Example 9. Mice treated in combination with MCK.miR-29c / microdystrophin were compared to untreated mdx / utrn. +￥- It showed protection from force loss compared to muscle (Figure 16c). These data indicate that fibrosis reduction and gene replacement increase both absolute and specific force and significantly protect muscle from contraction-induced injury.

[0126] Example 12 Early combination therapy increases muscle hypertrophy and hyperplasia. Co-delivery of rAAV expressing microdystrophin with rAAV.MCK.miR-29 did not increase the total weight of the injected gastrocnemius muscle compared to either injection alone, 3 months after injection (Figure 17a). Muscle fiber diameter was also measured. miR-29c / microdystrophin combination therapy showed an increase in mean fiber size. mdx / utrn + / - Control group: miR-29c / microdystrophin treatment mdx / utrn + / - In comparison, the average diameter increased from 28.96 to 36.03 μm (Figure 17b). Co-delivery resulted in a shift towards wild-type fiber size distribution (Figure 17c). 1 mm in miR-29c / microdystrophin combination therapy 2 The number of muscle fibers per unit area was significantly lower than in untreated mice and wild-type mice (Figure 17d, ***p<0.01, ****p<0.0001).

[0127] References 1. Hoffman, E.P., Brown, R.H., Jr. & Kunkel, L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919 - 928 (1987). 2. Straub, V. & Campbell, K.P. Muscular dystrophies and the dystrophin - glycoprotein complex. Curr Opin Neurol 10, 168 - 175 (1997). 3. Sacco, A., et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx / mTR mice. Cell 143, 1059 - 1071 (2010). 4. Wallace, G.Q. & McNally, E.M. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol 71, 37 - 57 (2009). 5. Zhou, L. & Lu, H. Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol 69, 771 - 776 (2010). 6. Desguerre, I., et al. Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J Neuropathol Exp Neurol 68, 762 - 773 (2009). 7.Kim, J., et al.microRNA-directed cleavage of ATHB15 mRNA regulates vascular development in Arabidopsis inflorescence stems.Plant J 42, 84-94 (2005). 8.Ambros, V.MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing.Cell 113, 673-676 (2003). 9.Eisenberg, I., et al.Distinctive patterns of microRNA expression in primary muscular disorders.Proc Natl Acad Sci U S A 104, 17016-17021 (2007). 10.Jiang, X., Tsitsiou, E., Herrick, S.E.& Lindsay, M.A. MicroRNAs and the regulation of fibrosis.FEBS J 277, 2015-2021 (2010). 11.van Rooij, E., et al.Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.Proc Natl Acad Sci U S A 105, 13027-13032 (2008). 12.Cacchiarelli, D., et al.MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin / nNOS pathway.Cell Metab 12, 341-351 (2010). 13.DiPrimio, N., McPhee, S.W.& Samulski, R.J.Adeno-associated virus for the treatment of muscle diseases: toward clinical trials.Curr Opin Mol Ther 12, 553-560 (2010). 14.Mendell, J.R., et al.Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D.Ann Neurol 68, 629-638 (2010). 15.Mendell, J.R., et al.Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins.Ann Neurol 66, 290-297 (2009). 16.Mendell, J.R., et al.A phase 1 / 2a follistatin gene therapy trial for becker muscular dystrophy.Molecular therapy : the journal of the American Society of Gene Therapy 23, 192-201 (2015). 17.Carnwath, J.W.& Shotton, D.M.Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles.J Neurol Sci 80, 39-54 (1987). 18.Coulton, G.R., Morgan, J.E., Partridge, T.A.& Sloper, J.C. The mdx mouse skeletal muscle myopathy: I.A histological, morphometric and biochemical investigation.Neuropathol Appl Neurobiol 14, 53-70 (1988). 19.Cullen, M.J.& Jaros, E.Ultrastructure of the skeletal muscle in the X chromosome-linked dystrophic (mdx) mouse.Comparison with Duchenne muscular dystrophy.Acta Neuropathol 77, 69-81 (1988). 20.Dupont-Versteegden, E.E.& McCarter, R.J.Differential expression of muscular dystrophy in diaphragm versus hindlimb muscles of mdx mice.Muscle Nerve 15, 1105-1110 (1992). 21.Stedman, H.H., et al.The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy.Nature 352, 536-539 (1991). 22.Deconinck, A.E., et al.Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy.Cell 90, 717-727 (1997). 23.Grady, R.M., et al.Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy.Cell 90, 729-738 (1997). 24.Love, D.R., et al.An autosomal transcript in skeletal muscle with homology to dystrophin.Nature 339, 55-58 (1989). 25.Tinsley, J.M., et al.Primary structure of dystrophin-related protein.Nature 360, 591-593 (1992). 26.Tinsley, J., et al.Expression of full-length utrophin prevents muscular dystrophy in mdx mice.Nat Med 4, 1441-1444 (1998). 27.Squire, S., et al.Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system.Hum Mol Genet 11, 3333-3344 (2002). 28.Rafael, J.A., Tinsley, J.M., Potter, A.C., Deconinck, A.E.& Davies, K.E.Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice.Nat Genet 19, 79-82 (1998). 29.Zhou, L., et al.Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice.J Neurol Sci 264, 106-111 (2008). 30.Gutpell, K.M., Hrinivich, W.T.& Hoffman, L.M.Skeletal Muscle Fibrosis in the mdx / utrn+ / - Mouse Validates Its Suitability as a Murine Model of Duchenne Muscular Dystrophy.PloS one 10, e0117306 (2015). 31.Rodino-Klapac, L.R., et al.Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model.Human molecular genetics 22, 4929-4937 (2013). 32.Cushing, L., et al.MIR-29 is a Major Regulator of Genes Associated with Pulmonary Fibrosis.Am J Respir Cell Mol Biol (2010). 33.Roderburg, C., et al.Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis.Hepatology 53, 209-218 (2011). 34.Nevo, Y., et al.The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy / dy mouse model of muscular dystrophy.PloS one 6, e18049 (2011). 35.Rodino-Klapac, L.R., et al.A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.J Transl Med 5, 45 (2007). 36.Mulieri, L.A., Hasenfuss, G., Ittleman, F., Blanchard, E.M.& Alpert, N.R.Protection of human left ventricular myocardium from cutting injury with 2,3-butanedione monoxime.Circ Res 65, 1441-1449 (1989). 37.Rodino-Klapac, L.R., et al.Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery.Molecular therapy : the journal of the American Society of Gene Therapy 18, 109-117 (2010). 38.Grose, W.E., et al.Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer.PloS one 7, e39233 (2012). 39.Liu, M., et al.Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury.Mol Ther 11, 245-256 (2005).

Claims

1. A plasmid containing the microdystrophin gene that encodes the amino acid sequence shown in Sequence ID No.

8.

2. A plasmid containing a microdystrophin gene, wherein the gene comprises a nucleotide sequence encoding the amino acid sequence shown in Sequence ID No.

8.

3. The plasmid according to claim 1 or 2, further comprising a selectable marker.

4. The plasmid according to any one of claims 1 to 3, further comprising, in the 5' to 3' direction, an inverse terminal repeat (ITR), a muscle-specific regulatory element, a chimeric intron sequence, the microdystrophin gene, a polyA tail, and an ITR.

5. The plasmid according to claim 4, wherein the muscle-specific regulatory element comprises the nucleotide sequence shown in SEQ ID NO: 10 or SEQ ID NO:

11.

6. The plasmid according to claim 4 or 5, wherein the chimeric intron sequence comprises nucleotides 844 to 993 of SEQ ID NO:

9.

7. The plasmid according to any one of claims 4 to 6, wherein the polyA tail comprises nucleotides 4585 to 4640 of sequence number 9.

8. The plasmid according to any one of claims 1 to 7, wherein the plasmid lacks the AAV rep and cap genes.

9. A composition comprising a plasmid according to any one of claims 1 to 8 for use in a method for producing a functional microdystrophin protein, wherein the method is: Bringing the host cell into contact with the plasmid, Expressing functional microdystrophin protein in the aforementioned host cells and A composition containing the following:

10. A bacterial cell comprising the plasmid described in any one of claims 1 to 8.

11. Packaging cells comprising the plasmid according to any one of claims 1 to 8.

12. The packaging cells according to claim 11, wherein the packaging cells include 293 cells, MRC-5 cells, WI-38 cells, Vero cells, or FRhL-2 cells.

13. A method for producing recombinant AAV (rAAV) particles, wherein the method is: Culture packaging cells containing the plasmid described in any one of claims 1 to 8, The rAAV particles are recovered from the supernatant of the aforementioned cells. Methods that include...

14. The method according to claim 13, further comprising purifying the rAAV particles from the cell supernatant.

15. The method according to claim 13 or 14, wherein the packaging cells include 293 cells, MRC-5 cells, WI-38 cells, Vero cells, or FRhL-2 cells.

Images